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ABSTRACT 
 The cellular prion protein (PrP) has been shown to act as a receptor for soluble 
oligomers of amyloid-beta (Aβ), an ~4 kDa amyloidogenic peptide that is found in 
neuritic plaques that are a pathological hallmark of Alzheimer’s disease (AD). 
Oligomeric forms of the Aβ peptide are thought to be synaptotoxic, and have been shown 
to produce PrP-dependent dendritic spine loss, suppression of long term potentiation 
(LTP), and behavioral changes in mouse models of AD.  However, the specific molecular 
interactions between PrP and Aβ have not been fully characterized.  In this work, we 
conducted a robust examination of the kinetic processes leading to Aβ fibril formation, 
and present evidence that PrP significantly inhibits Aβ polymerization. Using established 
mathematical models of polymerization kinetics, we show that inhibition is based on 
binding between PrP and the ends of Aβ filaments, an interaction that blocks elongation. 
To support these results, we conducted multiple binding assays to show that PrP binds to 
monomers of Aβ with low affinity, oligomers with intermediate affinity, and to fibrils 
with high affinity. These results extend upon previous studies, which have focused only 
on the interaction between oligomeric Aβ and PrP. To better understand the molecular 
interactions required for binding and inhibition of polymerization, we performed assays 
  viii 
with a series of PrP deletion mutants, which revealed that low-affinity binding to Aβ 
monomer is dependent on the presence of the C-terminal domain of PrP. This domain is 
also required for Aβ polymerization inhibition. Based on our results, we propose a model 
in which the unstructured N-terminal domain of PrP binds to the ends of Aβ fibrils, while 
the C-terminal domain interrupts the docking of new monomers to fibril ends, in part 
through competing for similar binding sites. This study provides an important 
contribution to our understanding of the PrP-Aβ interaction that leads to synaptoxicity. 
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CHAPTER ONE: INTRODUCTION 
1.1 Alzheimer’s Disease 
a. History 
 Senile dementia was a familiar phenomenon to the medical community when 
Alois Alzheimer first described the distinct symptoms displayed by Auguste Deter, a 51-
year old German woman who was a patient at the Frankfurt insane asylum where he 
worked  (1). Deter was suffering from what appeared to be a rare form of dementia, 
which was not only pre-senile but also startlingly rapid in its progression, both of which 
drew Alzheimer’s attention. In a seminal case study published in 1907, he presented 
findings of a post-mortem examination of Deter that described a brain in an advanced 
state of atrophy, combined with histological presentation of tangled neurofibrils and 
distinct foci (1). The disease was described and named ‘Alzheimer’s disease’ by 
colleague Emil Kraepelin in a text published in 1910 (2), but it was not until nearly seven 
decades later, in 1976, that Robert Katzman published an editorial that was instrumental 
in drawing attention to Alzheimer’s disease (AD) as a leading cause of death among the 
elderly (3). Katzman’s publication and advocacy prompted a dramatic increase in 
research devoted to AD. In the decades that followed, the neurofibrillary tangles and 
neuritic plaques that Alzheimer had described in 1907 were shown to contain misfolded 
aggregates of tau and amyloid-beta (Aβ), respectively (4-6). With these molecular agents 
identified, research has focused on cultivating a greater understanding of the mechanisms 
of AD, building better diagnostic models, and developing targeted therapeutics that could 
delay the course of the disease. 
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b. Symptoms 
 AD is a progressive disease, with a time course of 2 to 20 years, characterized 
first by minor memory loss and disorientation (7). Over time, people with AD suffer 
increased memory loss, confusion, aphasia, and frequent mood swings; they cease to 
recognize close friends and family members, and are prone to ‘wandering’ behavior that 
can place an additional burden on caregivers. In late stages, AD robs individuals of their 
ability to perform basic tasks, including eating and moving of their own volition, and at 
this point they become dependent on full-time care and medical intervention. The cause 
of death for those with AD can vary; usually a combination of decreased food intake and 
loss of continence and mobility make a person, in the terminal stages of the disease, 
particularly susceptible to infection or cardiac events (8). Current treatment options are 
limited to palliative measures and drugs designed to replace essential neurotransmitters 
lost in late stages of the disease (9); thus, the development of AD therapeutics is a high 
priority in the biomedical research community. 
c. Molecular pathology  
 The pathological changes that Alzheimer first described in 1907 (1) are now 
central to the diagnosis of AD, but how and why these changes produce the specific 
symptoms of the disease, and, by extension, how to design therapeutic approaches to 
combat these pathological changes, are questions still under investigation. The most 
striking physiological manifestation in late stages of AD is a visible decrease in brain 
mass through cortical and hippocampal atrophy (Figure 1). However, this effect has 
significant overlap with the effects of normal aging (10-12).  In earlier stages, atrophy 
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appears to be proceeded by synaptic loss localized in the entorhinal cortex and CA1 
region of the hippocampus (13-16). Until recently, however, determining the extent of 
synapse loss in the brain required post-mortem analysis or surgical biopsy. With the 
overarching goals of improving disease diagnosis and treatment through a better 
understanding of the molecular mechanisms of AD, researchers have focused on 
deciphering changes in relative levels, localization, and aggregation states of amyloid-
beta (Aβ) and tau, the two proteins associated with the histopathological hallmarks of the 
disease.  
 Aβ, a 40-42 residue polypeptide chain formed during proteolytic cleavage of the 
amyloid precursor protein (APP), is the dominant component of AD plaques (4,17). 
Plaques are characterized by a highly concentrated central region rich in amyloid deposits 
composed of the fibrillar form of Aβ; these cores are surrounded by dystrophic neurites 
(Figure 2), and associated with local synapse loss and inflammation (18-21). 
Topographic distribution of plaques is focused in the neocortex in early AD patients, but 
accumulation of amyloid deposits spreads to the allocortex, including the CA1 region, at 
later stages of disease (Figure 3)(22,23). While total plaque load tends to be elevated in 
individuals with early AD, the distribution and density of plaques does not correlate well 
with progression of symptoms (24,25). This piece of evidence has led to a shift in focus 
from plaque-associated Aβ fibrils to soluble oligomers of Aβ as the more relevant 
synaptotoxic species, a hypothesis discussed in more depth below. 
 The second pathological hallmark of AD, neurofibrillary tangles (NFTs) are 
composed of aggregated, hyperphosphorylated tau, which can be detected both in living 
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neurons and as a protease-resistant ‘ghost’ of the cell body after the cell has died (Figure 
2) (26,27). In contrast with plaques, NFTs are well-correlated with progressive neuronal 
loss; particularly in layer II of the entorhinal cortex and the CA1 region of the 
hippocampus (Figure 4) (14,28). In addition, positron emission tomography (PET) scans 
show correlation between tau staining and early memory deficits that may, along with Aβ 
detection using Pittsburgh compound B (PiB), serve as a predictor for the progression of 
AD (29). The connection between NFTs and neuron loss, despite topographic correlation, 
has not been determined; interestingly, knockout of tau results in transgenic mouse 
models that suffer no detectable behavioral abnormalities and may be, in fact, resistant to 
Aβ oligomer toxicity (30-32). The role of tau in neurodegenerative disorders is not 
limited to AD; there are a host of other diseases known as tauopathies in which tau is 
thought to be the central contributor to synaptic loss (33,34). Recently published studies 
propose that, like Aβ, tau may assemble into soluble oligomers that are more cytotoxic 
than their insoluble fibrillar counterparts (35,36). 
 Temporal evidence from post-mortem studies, cerebral spinal fluid (CSF) 
analysis, and imaging studies using PET suggest that Aβ deposition begins prior to major 
development of NFTs (29). This has led to the hypothesis that Aβ is the key pathogenic 
molecule that leads to downstream effects including changes in tau post-translational 
modification (37,38). A feedback mechanism has also been proposed in which NFTs 
create an environment that speeds the process of Aβ aggregation and plaque formation 
(37). These theories have been bolstered by data demonstrating that suppression of tau 
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expression in both neuronal cell culture and mouse models of AD correlates to a delay in 
Aβ-dependent neuronal deficits (30). 
d. Molecular genetics  
 Much of what we know about the molecular genetics of AD comes from studies 
of autosomal dominant familial Alzheimer’s disease (FAD) (27,39,40). Most mutations 
associated with this rare disorder disrupt normal proteolytic processing of APP, causing 
an increased amount of Aβ produced through proteolytic cleavage or favoring the 
production of the longer, more aggregation-prone Aβ 1-42 isoform (41). A cluster of 
mutations have been identified in the APP gene which have been proposed to impact 
proteolytic cleavage, and have been shown to accelerate Aβ deposition in mouse models 
(41,42). One of the more well-known mutations is the Swedish mutation 
(K670N/M671L), which increases Aβ production through β-secretase (BACE1) cleavage 
and is a standard transgenic mouse model of AD (43-45). It has also been shown that 
duplication of the APP locus, located on chromosome 21, leads to FAD and is associated 
with the high prevalence of early-onset AD in people with Down syndrome (46,47). 
Furthermore, mutations have been identified in the genes PSEN1 and PSEN2, which 
produce presenilin 1 and 2, both components of the γ-secretase complex that drives 
production of Aβ (48-51). Arguably the link between these mutations and FAD is not 
entirely clear since, in addition to APP cleavage, secretases are also involved in 
processing of other proteins including proteins in the Notch family; moreover, changes in 
activity may produce a general shift in neuronal health that leads to increased 
susceptibility to neurodegeneration (52).   
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 Only one genetic risk factor has shown consistent and robust association with 
sporadic AD (9). Apolipoprotein E4 (apoE4) is one of four variants of the human 
apolipoprotein gene that produces proteins involved in lipid trafficking. The presence of 
the apoE4 allele greatly increases risk of developing sporadic AD; statistically the mean 
age of onset for AD decreases from 84 years with no copies of the allele to 68 years with 
two (53). Proposed mechanisms for this finding vary; apoE proteins are important 
cholesterol transporters in the brain, determining lipid redistribution after neuronal 
degeneration and potentially affecting many processes related to synapse repair, Aβ 
clearance, and cell signaling (54). Recent genome-wide association studies (GWAS) have 
identified other risk factors for sporadic AD including mutations in a variety of proteins 
which exhibit a wide range of functions; PLD3 (signal transduction), TREM2 
(inflammatory response), ADAM10 (neurogenesis, α-cleavage), and others (39,55) have 
been reported.  However, the apo E4 mutant remains the most significant predictor of 
AD, to date (56). 
  In contrast, tau mutations that can be directly linked to AD risk have not yet been 
described. Mutations in MAPT, the gene for tau, produce variant forms of tau that are 
aggregation prone and result in frontotemporal dementia (FTD), but not AD (9,57). This 
observation has lent strength to the hypothesis that Aβ aggregation proceeds formation of 
NFTs in AD. 
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1.2 Amyloid-beta (Aβ) 
a. Proteolytic processing of APP 
 Amyloid precursor protein (APP) is a transmembrane protein with a large 
extracellular domain (58). Three dominant isoforms (containing 695, 751, or 770 amino 
acids) are expressed, with the 695 amino acid isoform most prominent in the central 
nervous system. The cellular function of APP is not fully characterized; but it has been 
found that an elevation in APP levels results in an increase in medium-size neurites and 
indicates a role in neurotrophy (59). In addition, shRNA knockdown of APP in utero 
results in reduced neuronal migration in the cortex during development (60). APP was 
originally identified as the progenitor protein for Aβ (17), but the proteolytic processing 
pathway for APP is quite complex and produces several major cleavage products with 
multiple functions. During normal processing of APP, two pathways produce distinct 
cleavage products (Figure 5).  The extracellular domain is cleaved by α-secretase to 
produce soluble alpha-amyloid precursor protein (sAPPα), or by β-secretase to produce 
soluble beta-amyloid precursor protein (sAPPβ) (58). After this initial cleavage, the 
transmembrane domain is cleaved by γ-secretase, a proteolytic complex that includes 
presenilin 1 and 2, producing either the polypeptide p3 (Aβ 17-40/42) in cooperation with 
α-secretase, or Aβ 1-40/42  in cooperation with β-secretase (58)  .  
 Although Aβ is implicated in Alzheimer’s disease, several cleavage products of 
APP have been shown to have potential neuroprotective effects, particularly sAPPα. Not 
only has sAPPα been shown to play a strong role in neurotrophy (59,61), it has also been 
shown to protect against excitotoxicity (61-63), and to support synaptogenesis (64). 
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Interestingly, production of sAPPα precludes production of Aβ, leading to a potential 
dual effect in which a shift toward BACE1 processing and Aβ production is potentially 
associated with a decrease in natural neuroprotective functions. sAPPβ has also been 
implicated in axonal pruning (65), and Aβ itself may normally play a role in APP 
processing through negative feedback mechanisms (66,67); thus, proteolytic processing 
of APP may have opposing but complementary effects in the healthy brain. 
b. The amyloid cascade hypothesis 
 Simply put, the amyloid cascade  hypothesis of Alzheimer’s disease proposes that 
changes in the proteolytic processing of APP drive increases in Aβ production, which 
lead to the formation of acutely synaptotoxic Aβ oligomers and amyloid fibrils (68,69). 
Aβ aggregates are thought to promote neurodegeneration before becoming incorporated 
into senile plaques. In this model, the downstream effects of Aβ, including inflammation 
and changes in phospho-tau levels, carry the initial acute affects into a pervasive disorder 
of the brain resulting in AD (Figure 6).  
 Support for the amyloid cascade hypothesis comes from genetic studies linking 
increased expression or modified APP proteolysis with familial forms of AD (9). 
However, the molecular mechanisms of Aβ toxicity have not been fully characterized. 
Several studies have demonstrated that the extent of amyloid-rich plaques observed in 
AD brains correlates poorly with disease progression, despite evidence of local 
inflammation and neuritic dystrophy (18,20,21,24,25,70). On the other hand, the 
concentration of soluble Aβ in AD brain was found to be a much better predictor of 
progressive neurodegeneration (71-74).  Soluble Aβ, however, describes a wide range of 
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protein structures from monomeric or dimeric forms to large globular aggregates, and 
studies of the molecular mechanisms of toxicity have demonstrated varying effects using 
both synthetic and naturally occurring Aβ (69,75).  The molecular mechanisms of Aβ-
dependent cytotoxicity, including the size and structure of particularly cytotoxic 
aggregates, remain to be described.  
c. Molecular mechanisms of Aβ toxicity 
 Aβ oligomers, ranging in size from dimeric forms to large, globular assemblies of 
100mer or more, have been purified from AD brain tissue; a similar range of molecular 
species have been produced in vitro from purified Aβ peptide (69).  Oligomers of all 
sizes, generated from a variety of extraction methods, have been shown to have 
unequivocal effects on synaptic plasticity; suppression of long-term potentiation (LTP) 
(76-85), activation of long-term depression (LTD) (76,80), and retraction of dendritic 
spines (76,86). All of these physiological responses are linked to learning and memory, a 
connection that has been born out in various in vivo studies demonstrating impairment of 
learning and memory tasks with perfusion of Aβ oligomers (81,87).  
 Shanker et al. found that both N-methyl-D-aspartate receptor (NMDAR) and 
metabotropic glutamate-5 receptor (mGluR5) antagonists could block Aβ oligomer-
dependent changes in LTP and LTD, and excitotoxicity in neurons; these observations 
were corroborated in follow-up studies (76,79,80,88). Aβ oligomers also cause Fyn 
kinase activation and changes in patterns of tau phosphorylation, suggesting a possible 
link between the two pathological hallmarks of AD (38,86,89,90). On the cell surface, Aβ 
oligomers have been shown to interact directly with NMDAR, as well as a host of other 
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targets including P/Q-type calcium channel, AMPAR, apoE, and the cellular prion 
protein (PrPc) (91). Together, these multiple proposed mechanisms of toxicity offer a 
variety of potential therapeutic targets, although, as discussed below, few have shown 
robust clinical efficacy. 
 In contrast, the molecular mechanisms of Aβ fibril toxicity are not well 
characterized. Conflicting results have shown fibrillar Aβ to be toxic (92-95) in cell death 
assays or non-toxic (82,96,97) depending on the preparative method used to generate the 
fibrils. A connection between fibrils and toxicity is unclear despite the appearance of 
dystrophic neurites and local inflammation surrounding Aβ amyloid plaques; the 
observation of diffuse oligomers associated with the plaque surface has complicated the 
idea that fibrils alone actually cause localized synaptotoxicity (98). Notably, it has been 
hypothesized that there may be Aβ fibril structures unique to AD (95,99). Overall, 
inconsistencies in studies aimed at determining the cellular effects of Aβ fibrils seem 
more prevalent than similar analyses of oligomers, leading to a predominant hypothesis 
that oligomers are the cytotoxic species.  
d. Aggregation kinetics 
 The polymerization of Aβ subunits into fibrils can be described as a stepwise 
reaction that is easily replicated in vitro. Thioflavin T (ThT) monitoring is the standard 
method for analysis of Aβ polymerization; binding of ThT to fibrils, as they form in 
solution, produces sigmoidal-shaped curves that provide clues about the aggregation 
process through mathematical modeling (Figure 7A) (100). Data from structural studies 
of Aβ using X-ray diffraction, solid state NMR and transmission electron microscopy, 
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when combined with results from kinetic analyses, present a clearer picture of the 
multiple molecular states and transitions of Aβ as it undergoes self-assembly into 
oligomeric and fibrillary forms. 
 In the early stages of Aβ polymerization, monomeric peptide conversion from 
random coil or α-helix to β-turn-β structure drives the self-assembly of oligomers and 
protofilaments (101,102). This lag phase in the aggregation process, during which no 
changes in ThT signal are observed, is the rate-limiting, primary nucleation step; in this 
stage, the assembly of polymers proceeds to formation of an appropriate template which 
will allow construction of long, β-sheet rich filaments. Following nucleation, the reaction 
enters an exponential growth phase characterized by rapid elongation of protofilaments, 
with new monomers binding to filament ends, and ordered stacking, a process that results 
in formation of a cross-β structure with parallel, in-register β-sheets (94). A unique 
feature of Aβ polymerization, as reflected in the sigmoidal aggregation curves, is the 
feedback of secondary nucleation processes in which new oligomers are created through 
nucleation that occurs on the surface of fibrils (100). The polymerization reaction reaches 
equilibrium when maximal fibril mass is achieved and nearly all monomers are 
incorporated into fibrils. Figure 7B summarizes the steps and associated structures of the 
polymerization reaction. 
The conformation of mature Aβ fibrils is typical of amyloid fibrils, i.e. highly 
ordered, non-branching structures composed of β-strands oriented perpendicularly to the 
long axis of the fibril (102,103). The mature fibril is constructed from individual 
filaments which associate laterally, creating twist or ribbon morphologies depending on 
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the arrangement of the filaments relative to each other (104). There is some evidence that 
initial filament structure will determine the final structure of fibrils, and that ‘seeding’ 
polymerization of Aβ monomers with fibrils isolated from AD brain will produce distinct 
structures (99). This has important relevance to toxicity studies performed with fibrils 
generated in vitro, as the ‘correct’ cytotoxic structure may be lacking.  
e. Oligomer formation and size 
Based on reaction rate constants, Aβ filament elongation has been determined to 
be a first order kinetic process with a single monomer attaching to the end of each 
protofilament during the growth phase (94,105). Given this model, where do oligomers, 
the proposed toxic species of Aβ, fit in? In Figure 7B, we illustrate oligomers as dimers 
of Aβ; dimeric forms of Aβ have previously been purified from AD brain and isolated 
from polymerization reactions using PICUP (76,78,89,106). Dimers have been shown to 
be toxic; however, metastable protofibrils (107,108), globular oligomers (109), and high 
molecular weight assemblies (83) have also been purified from AD brains and shown to 
induce cytotoxic effects. Thus, it is important to note, that dimeric Aβ may not be the 
only toxic species of oligomer described in the literature. Interestingly, the original 
method for synthetic production of oligomers from Aβ involved the addition of clusterin, 
which halted amyloid fibril formation through generation of globular oligomers (90). 
Other methods have been used for production of soluble Aβ oligomers including a well-
established protocol featuring treatment of Aβ with HFIP (110). Methods employed to 
generate amyloidogenic Aβ oligomers are distinct from standard polymerization reactions 
used to produce Aβ amyloid fibrils; this fact may support the idea that oligomers are off 
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the amyloid fibril forming pathway (off-pathway aggregates) in the kinetic process, a 
hypothesis that is still hotly debated (111).  
Arguing for amyloidogenic or on-pathway oligomer formation, Cohen et al. 
propose that the bulk of oligomers results from secondary nucleation during 
polymerization, which is characterized by Aβ monomer conversion to oligomer through 
transient interactions with fibril surfaces (100). In in vitro studies, only a small pool of 
detectible soluble oligomers develops from a fixed concentration of monomers present at 
the start of polymerization. However, it has been proposed that Aβ plaques in the brain 
exhibit an equilibrium state between continuous absorption and shedding of lower 
molecular weight aggregates (98,112); this, combined with cellular secretion of Aβ 
monomers, creates a constant source for newly formed oligomers. 
f. Therapeutic approaches targeting Aβ 
 Molecular pathology and genetic studies have elucidated the key role that Aβ 
plays in the development and progression of AD. With advancements in our 
understanding of the pathobiology of AD, researchers seek to design therapeutic 
strategies that target the initial production of Aβ peptide, slow the progress of 
aggregation, and/or reduce plaque load and encourage clearance of Aβ.  
 Secretase inhibitors are a common class of compounds being tested in clinical 
trials for efficacy in reducing Aβ plaque load and slowing neurodegeneration (9). 
Specifically, preventing Aβ production by blocking BACE1 proteolysis of APP with 
BACE1 inhibitors appears to be a promising therapeutic strategy (113). Recently, clinical 
testing of the BACE1-inhibitor, verubecestat, initially showed encouraging results; data 
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from the study indicated low drug toxicity and mildly positive effects in clearing Aβ and 
sAPPβ in drug-treated AD patients (114). However, cancellation of phase 3 trials was 
recently announced due to lack of effectiveness in alleviating symptoms. Targeting 
another piece of the APP proteolytic pathway, development of γ-secretase inhibitors has 
been plagued with problems stemming from undesirable side effects, most likely due to   
changes in γ-secretase cleavage of other targets in the CNS (9,115,116). 
 Immunotherapeutic targeting of Aβ, another prominent strategy in combatting 
AD, was one of the first approaches directed at clearance of Aβ. Early trials of an AD 
‘vaccine’ were cancelled due to encephalitis in the study group; a follow-up study with 
modified antibodies showed significant decreases in Aβ load compared to controls, but 
no impact on the course or severity of disease (117). Many other Aβ antibodies have been 
tried as well; more recently, bapineuzumab, a humanized antibody targeting the N-
terminal region of Aβ, yielded similar failures in clinical trials (118). Similarly, 
solanezumab, another Aβ monoclonal antibody, recently failed phase 3 trials for 
treatment of mild AD (119).  
 Some investigators in the AD field view these clinical research failures as 
evidence that the amyloid cascade hypothesis is invalid; however, this conclusion may be 
premature. Part of the problem lies in the fact that an accurate diagnostic test for early 
AD does not yet exist; drugs that target the Aβ production pathway must be administered 
prior to accumulative effects, but so far have only been tested after Aβ accumulation has 
progressed to abnormal levels.  Until improved diagnostic tools are established, it will be 
difficult to move forward with any therapeutic designed to target the first stages of the 
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amyloid cascade. Moreover, it has been suggested that, in order to ameliorate the effects 
of one toxic aggregate of Aβ, all levels of the amyloid pathway must be addressed in a 
combined therapeutic strategy (120). Therefore, a current challenge in the field of AD 
therapeutics is the development of pre-symptomatic diagnostic tools that will allow these 
strategies to be applied with the highest possible efficacy. 
 The only drugs currently approved by the FDA for treatment of AD do not target 
Aβ. Four acetylcholinesterase inhibitors (e.g., Donepezil) are currently available and 
being used to treat the symptoms of AD. These drugs were designed to respond to 
decreases in the neurotransmitter, acetylcholine, a feature that was noted in brains from 
patients with AD and other forms of dementia (121). Memantine is an NMDA receptor 
antagonist used to treat moderate to severe AD by dampening the effects of excitotoxicity 
(122). Neither acetylcholinesterase inhibitors nor NMDA receptor antagonists have been 
shown to reverse or significantly slow the progress of the disease (9). 
g. The role of chaperones in Aβ polymerization 
 An alternate approach to traditional drug targeting with antagonistic small 
molecules lies in manipulation of the Aβ aggregation pathway. Chaperones are molecular 
facilitators of protein folding and key players in maintaining proteostasis in healthy cells 
(123). As such, they play a natural protective role against neurodegeneration by both 
directly and indirectly preventing the misfolding and polymerization of cytotoxic 
aggregates (124). Chaperones have been shown to reduce the cytotoxicity of Aβ 
oligomers by preventing the oligomers from interacting with the cell membrane and 
incorporating them into larger, less toxic aggregates (125). This has led to the proposal 
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that pharmacological chaperones could have therapeutic potential through their ability to 
disrupt the processes that create cytotoxic Aβ oligomers. 
 Functionally, several different modes of action have been proposed for 
chaperones as protective molecules in AD progression. Following on the hypothesis that 
secondary nucleation is the primary process involved in forming toxic oligomers, Cohen 
et al. proposed a therapeutic model of inhibition and were able to show that the Brichos 
domain, a 100-amino acid domain that has been shown to facilitate folding in a wide 
range of proteins, can successfully inhibit secondary nucleation and mitigate toxicity 
(126). DNAJB6, another naturally occurring chaperone, was shown to significantly delay 
primary nucleation at sub-stoichiometric ratios (127). Chaperones can also sequester Aβ 
oligomers into hypothetically less toxic amyloid fibrils; the small molecule, O4, has been 
shown to rescue suppression of LTP in hippocampal brain slices through this mechanism 
(128). Although these studies suggest that chaperones may function in mitigating amyloid 
formation, the role of pharmacological chaperones as therapeutics is so far theoretical; no 
successful tests have been conducted to demonstrate their efficacy in animal models. 
1.3 The prion protein 
a. Cellular function  
 The cellular prion protein (PrPc or PrP) is a ubiquitous 208-209 amino acid 
glycosylphosphatidylinositol (GPI)-anchored glycoprotein that is expressed in all tissues 
(129). As with APP, the native function of PrP is not yet clear, although proteolysis of the 
extracellular domain is thought to play a role in its regulation (129,130). In the central 
nervous system, PrP is highly expressed and while multiple functions have been 
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attributed to the protein, knockout animal models of PrP appear phenotypically normal 
(131). However, deletion mutants of PrP have produced marked phenotypes; significant 
neurodegeneration was demonstrated in a model with expression of truncated forms of 
PrP and embryonic lethality was observed with a central region deletion mutant (PrP 
∆105-125) (129). These phenotypes were partially or fully rescued by co-expression of 
wild-type PrP. 
b. Prion diseases 
 The misfolded form of PrP, PrPSc, was originally identified as the infectious agent 
in a category of neurodegenerative diseases collectively called transmissible spongiform 
encephalopathies (TSEs) (132). The hypothesis that a single protein could confer 
infectivity was revolutionary at the time of its discovery, but it is now well-established 
that PrPSc acts as a template to create a similar misfolded conformation in PrP (133-136). 
TSEs can be sporadic (most common), familial, or infectious (137). Classically, PrP 
conversion was thought to be limited by amino acid sequence homology and thus, 
unlikely to cross species barriers (138-140). However, the recognition of new variant 
Creutzfeldt-Jakob disease (nvCJD), a TSE in humans that appears to have originated in 
infected beef, has raised concerns that the barrier does not sufficiently protect humans 
from infectious forms transmitted from other animals (141,142).  
 Much like Aβ plaques in AD, PrPSc levels do not correlate well with disease 
symptoms (143,144). A recent hypothesis proposes that intermediate oligomeric species 
of PrP are the true synaptotoxic molecules. There is some evidence that PrP-PrPSc 
intermediates, as well as fibrillar forms, produce toxic effects (145-149); however, it is 
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still unclear whether PrPSc is directly toxic or an off-pathway form of a toxic species, or if 
misfolding of PrP simply produces gain or loss of function effects similar to those seen in 
deletion mutants of PrP. 
c. Native structure 
 The prion protein has two domains, an unstructured N-terminal domain and a 
globular C-terminal domain (Figure 21) (150). The flexible N-terminal domain spans 
from residues 23-128 and contains two polybasic regions, one at the extreme N-terminus 
(residues 23-28) and the other located at residues 100-109 (151). In addition, the N-
terminal domain contains an octapeptide repeat (OR) that spans residues 51-91 and binds 
copper.  The structured C-terminal domain has been characterized by both NMR and 
crystallography; this region contains α-helices spanning residues 144-154, 179-193, and 
200-217, and β-strands located at 128-130 and 161-164 (on either side of the first α-helix) 
(152). The second and third α-helices are connected by a disulfide bond. 
1.4 Interaction between prion protein and Aβ 
a. Original binding studies  
 Lauren et al. conducted a study in 2009 designed to identify receptors for 
cytotoxic Aβ oligomers (84). This study featured the use of biotinylated synthetic Aβ 
oligomers to screen cDNA from a mouse brain library for binding; from a total of 250000 
clones, 2 PrP-expressing cell lines were found to bind the labelled Aβ oligomers. Binding 
was found to be specific to Aβ oligomers in the cell lines, but slightly less so in in vitro 
pull-down assays. Anti-PrP antibodies 6D11 (epitope 93-109) and 8G8 (epitope 95-110) 
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greatly decreased PrP-Aβ oligomer binding, as did deleting PrP residues 23-95. Aβ 
oligomers exhibited PrP-expression-dependent suppression of LTP in CA1 hippocampal 
slices, indicating that one of the standard assays for early synaptic changes was 
responsive to PrP deletion. In a follow-up study, Gimbel et al. created a transgenic mouse 
model by crossing an AD background (containing both the Swedish APP and presenilin 1 
mutations) with a PrP knock-out to show that elimination of endogenous PrP expression 
abrogated deficits in learning and memory (153). In this model, Aβ levels were not 
affected by the PrP knockout and it was also noted that PrP deletion significantly slowed 
axonal degradation.  
b. Binding sites 
 Freir et al. sought to validate the results of Lauren et al. and identify additional 
antibodies that could potentially block binding between PrP and Aβ (78). Notably, they 
used Aβ oligomers purified from AD brain, as well as synthetically produced oligomers, 
and found that both forms displayed PrP-dependent suppression of LTP. ICSM35 
blocked binding, a result that was in agreement with inhibition by 6D11, and consistent, 
as both antibodies recognize the same PrP epitope. ICSM18, which recognizes the first α-
helix of PrP, also blocked binding; the decreased binding of PrP to Aβ in the presence of 
ICSM18 was attributed to steric hindrance and thus, related to the size of the oligomers. 
Chen et al. and Fluharty et al. identified the Aβ binding site locations on PrP through 
testing of a series of deletion mutants; binding occurred at two polybasic regions on the 
unstructured N-terminal domain of PrP, residues 23-27 and 95-110 (154,155). 
Subsequently, Klyubin et al. administered humanized ICSM18 to rats and demonstrated 
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that the antibody could block synaptotoxic effects from injected human AD brain extract 
(81). 
c. Size of aggregates 
 As stated, Freir et al. posited that, since the antibody did not recognize either of 
the known binding sites for Aβ oligomers, the inhibitory effect of ICSM18 was due to 
steric hindrance of large, soluble Aβ oligomers binding to PrP (78). Kostylev et al. 
proposed that binding of high molecular weight (HMW) oligomers was crucial to 
synaptotoxicity by showing that oligomers purified from AD brain both bound to PrP and 
eluted as HMW species by gel chromatography (156). However, this work did not 
include acute toxicity studies and the proposal that HMW oligomers were the toxic 
species is not consistent with subsequent data showing that large molecular weight 
oligomers must be disaggregated before becoming synaptotoxic (83). Fluharty et al. 
conducted binding studies using surface plasmon resonance (SPR) to show that the N-
terminal domain of PrP binds with changing affinity to Aβ over time; peak binding was 
observed after 4 hours of incubation and indicated binding of oligomers formed during 
polymerization (155).  
 Other studies attempting to establish the size of PrP-binding Aβ aggregates 
provided highly varied results. Proposed specific binding interactions have been assigned 
to HMW oligomers isolated from brain (156,157), HMW synthetic oligomers (154), 
protofibrils formed from synthetic oligomer preparations (158), synthetic dimers and 
trimers (159), dimers purified from brain (78), and synthetic fibrils and protofibrils 
(80,160). Although apparently confusing, these results are actually in accordance with 
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general toxicity studies using Aβ oligomer preparations (see 1.2.c) and indicate that PrP 
may not be selective regarding its Aβ binding partners.  
d. Proposed mechanisms 
 Previous studies of Aβ oligomer toxicity have provided evidence supporting 
mechanisms dependent on N-methyl-D-aspartate receptor (NMDAR) and metabotropic 
glutamate-5 receptor (mGluR5) (76,79,88). Um et al. studied the relationship between 
these downstream mechanisms and PrP-dependent Aβ toxicity (86); Aβ oligomers 
isolated from AD brain initiated a Fyn-kinase dependent change in NMDAR expression 
levels at synaptic densities, creating a transient increase in surface NMDAR. These 
effects were associated with dendritic spine loss. However, a direct connection between 
Aβ oligomer binding to PrP and downstream Fyn kinase activation was unclear, as PrP is 
a cell-surface protein and Fyn is known to be cytosolic. It was hypothesized that a second 
cell-surface receptor was needed to activate Fyn and in a follow-up study, mGluR5 was 
identified as the receptor; expression of mGluR5 was necessary for Fyn kinase activation 
by Aβ oligomer (161). This raised the question of effect on LTD which Shankar et al. 
showed was elevated by activation of mGluR5 by Aβ oligomers (88). Hu et al. 
demonstrated that Aβ oligomers (both synthetic and purified from AD brain) were able to 
activate mGluR5 in a PrP-dependent manner (80).  
 So far, biochemical studies of PrP and Aβ associations have been consistent with 
data characterizing Aβ oligomer toxicity; while some contradictory results have been 
reported, much of these data are derived from transgene models of AD in which APP 
processing and Aβ production have been modified to create increased pools of Aβ (162-
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164). It is probable that the PrP-Aβ interactions, which appear to rely heavily on synaptic 
plasticity moderators, reflect an acute effect and local response to changes in Aβ 
production, bypassed in models which overproduce endogenous Aβ or participate in 
alternative APP proteolytic pathways. This would make study of PrP-Aβ interactions an 
excellent model for early stages of sporadic AD, during which acute local synaptic 
changes are hypothesized to pave the way for massive toxicity in later stages. 
e. Protective mechanisms 
 Fluharty et al. found that the N-terminal domain of PrP, a natural cleavage 
product of the protein, had a protective effect against the toxicity of Aβ (155). On 
administering Aβ oligomers in conjunction with PrP residues 23-111 to cultured 
hippocampal neurons, C. elegans or mice, the authors noted changes in post-synaptic 
markers and memory deficits indicating that PrP 23-111 had a protective effect against 
Aβ (155). Guillot-Sestier et al. also showed a protective effect of PrP 23-111 by 
demonstrating rescue of toxic effects in Swedish APP mutant cells and Aβ-secreting 
Chinese hamster ovary (CHO) cells (165). Natural (from AD brain) and synthetic Aβ 
oligomers were tested and the same effect observed in both cases. Together, these studies 
imply a potential neuroprotective role for the N-terminal cleavage product of PrP.  
f. Aggregation inhibition 
 An interesting outcome of studies examining the interaction between PrP and Aβ 
is the finding that PrP inhibits Aβ polymerization. Nieznanski et al. showed that PrP was 
able to block aggregation at sub-stoichiometric ratios, preventing Aβ fibril formation and 
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delaying the formation of toxic oligomer species (166). Younan et al. showed similar 
inhibition and proposed a trapping mechanism in which PrP bound to and stabilized 
oligomer forms of Aβ via residues 95-113 (167). This surprising effect raises more 
questions regarding PrP-Aβ interactions and how they may affect toxicity and disease 
processes in AD. The mechanisms of the inhibition effect of PrP have not been fully 
characterized and conflicting elements in studies produced by the two groups remain 
unresolved. 
1.5 Thesis objectives 
 Amyloid-beta (Aβ) oligomers are synaptotoxic aggregates of the Aβ peptide that 
are thought to be the key pathogenic species necessary to trigger neurodegeneration in 
AD (68,69). Previous studies have shown that the cellular prion protein (PrP) acts as a 
cell-surface receptor for Aβ oligomers (78,84). This interaction results in synaptoxicity, 
the mechanisms of which have been biochemically characterized (80,86). However, the 
size and molecular nature of the Aβ oligomers that trigger this effect have been poorly 
characterized; toxicity studies have reported data on a variety of Aβ oligomers ranging 
from dimers to fibrils and prepared using an assortment of methods. Aβ has been shown 
to be sensitive to initial conditions, raising the question of whether toxicity is an effect 
specific to oligomers or simply responsive to any preparation of Aβ with suitable 
solubility.  
 The polymerization kinetics for Aβ have been robustly described and may offer a 
better understanding of how aggregation processes are connected to pathology. PrP 
inhibits polymerization of Aβ, although there is some disagreement about the mechanism 
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(160,166,167). Polymerization inhibitors have potential as therapeutic agents, by 
modifying the pool of free toxic Aβ (105). In this case, clarifying the effect of PrP on Aβ 
polymerization could provide insight into intermolecular interactions and potentially 
explain the protective nature of PrP. 
 The objective of this thesis research is twofold:  to determine the specificity with 
which PrP binds to different preparations of Aβ and to determine the molecular 
mechanisms by which PrP inhibits Aβ polymerization. Based on previous studies, we 
hypothesized that PrP would bind specifically to oligomeric species of Aβ, reflecting its 
role as a receptor for toxic oligomers, and impacting polymerization processes through 
sequestration of oligomers, as suggested previously (167).  
 The specific aims are as follows: 
Aim 1: Characterize the mechanisms by which PrP inhibits Aβ polymerization 
a. Validate the effect of PrP on Aβ polymerization using thioflavin T (ThT) and 
fluorescence polarization (FP). 
b. Determine the effect of PrP on fibril seeding of Aβ polymerization. 
c. Apply kinetic models to Aβ polymerization curves to determine the mechanism of 
inhibition. 
Aim 2: Determine differential binding affinities of PrP for Aβ aggregates 
a. Validate binding of PrP to Aβ monomers, oligomers, and fibrils using surface 
plasmon resonance (SPR), dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA), and FP. 
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b. Determine which regions of PrP are required for binding to Aβ monomers and 
fibrils. 
c. Examine the effect of deletion mutants of PrP on Aβ polymerization inhibition. 
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Figure 1. Changes in gross morphology of the brain in AD.  
Progression of cortical and hippocampal atrophy in age-matched coronal slices of brains 
from an asymptomatic individual (top), mild AD (middle) and severe AD (bottom). 
Massive shrinkage of brain tissue is observable, particularly in the cerebral cortex, and 
the lateral ventricles are dramatically enlarged. Image courtesy of the National Institute 
on Aging/National Institutes of Health.  
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Figure 2. Histological characterization of Alzheimer’s disease (AD). 
Paraffin section of the brain of an AD patient showing neurofibrillary tangles (NFTs) and 
senile plaques (SPs). Solid arrows indicate healthy neurons, darkly-stained cell bodies 
contain NFTs or represent protease-resistant ‘ghosts’ of dead cells filled with NFTs. (A) 
indicates the core of a senile plaque, open arrows indicate dystrophic neurites clustered 
around the perimeter. Scale bar 50 µM. Fixative not stipulated. Reprinted from Selkoe, D. 
J. (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498 with 
permission from Elsevier. 
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Figure 3. Spatiotemporal spread of Aβ deposits in the neocortex and medial 
temporal lobe (MTL). 
Images from coronal sections of the brain from an earlier (A and B) and more advanced 
(C and D) case of AD. The Campbell Switzer silver stain used to stain these slices 
reveals Aβ deposits as dark spots. Aβ deposit distribution is more extensive throughout 
the neocortex in C , and deposits can be seen in the hippocampus in D. Arrows in A and 
C indicate Aβ deposits in the neocortex, in D arrows indicate the appearance of deposits 
in the CA1 region of the hippocampus. FD = fascia dentata Calibration bar A and C, 
10000 µm; B and D, 1666 µm. Reprinted from Thal, D. R., Rub, U., Orantes, M. & 
Braak, H. (2002) Phases of A beta-deposition in the human brain and its relevance for 
the development of AD. Neurology 58, 1791-1800. 
http://www.neurology.org/content/58/12/1791.long with permission. 
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Figure 4. Spatiotemporal spread of neurofibrillary tangles (NFTs) in the brain in 
AD. 
NFT density is indicated by shading. The area most affected at each stage of progression 
is indicated above the images, along with the number assigned to indicate severity of 
neurofibrillary pathology. Upper images show the cerebral cortex, lower images represent 
a mid-sagittal view of the brain. 4 = primary motor cortex; 3-1-3 = primary sensory 
cortex; 18 = associative visual cortex; Cg = cingulate cortex; Prec = precuneus; Amyg = 
amygdala; EC = entorhinal cortex; 17 = primary visual cortex. Reprinted with permission 
from Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. (2011) 
Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor  Perspectives 
in Medicine 1 Copyright Cold Spring Harbor Laboratory Press. 
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Figure 5. Proteolytic processing pathways of APP. 
Proteolytic cleavage of APP proceeds through two well-studied pathways, one leading to 
formation of non-amyloidogenic products and the other resulting in generation of 
amyloidogenic Aβ. The diagram in the left panel shows the non-amyloidogenic process 
with production of the fragment p3 and sAPPα following sequential cleavage of APP by 
α-and γ-secretases. The right panel illustrates successive processing of APP by BACE1 
and γ-secretase, reactions that are considered part of an amyloidogenic pathway with 
production of the amyloid-precursor cleavage fragment Aβ. Reproduced from O’Brien, 
R. J., and Wong, P. C. (2011) Amyloid Precursor Protein Processing and Alzheimer’s 
Disease. Annu Rev Neurosci 34, 185-204 with permission. 
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Figure 6. The amyloid cascade hypothesis. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell 
Biology Haass, C. & Selkoe, D. J. (2007) Soluble protein oligomers in 
neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. 
Cell. Biol. 8, 101-112 http://www.nature.com/nrm/journal/v8/n2/full/nrm2101.htm 
copyright 2007 
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Figure 7. Polymerization of Aβ. 
(A) Starting with a preparation of purified Aβ monomers, the polymerization of the 
protein can be followed by temporal monitoring of ThT fluorescence; ThT curves exhibit 
a sigmoidal shape indicating a rate-limiting, lag phase followed by a more rapid fibril 
growth period. (B) Both kinetic and structural studies have contributed to this model of 
Aβ polymerization. Primary nucleation is the rate-limiting, initial reaction step featuring 
production of oligomeric Aβ. Formation of protofilaments occurs in the exponential 
growth phase, characterized primarily by elongation. Mature fibrils catalyze formation of 
new oligomers through conversion of free monomer on the fibril surface, leading to 
secondary nucleation. 
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CHAPTER TWO: THE PRION PROTEIN INHIBITS AMYLOID-BETA 
POLYMERIZATION BY BINDING TO FIBRIL ENDS AND PREVENTING 
ELONGATION 
2.1 Summary 
 During polymerization, amyloid-beta (Aβ) converts from monomeric peptide to 
insoluble amyloid fibrils. The prion protein (PrP) is known to interrupt this 
polymerization process, delaying the formation of fibrils (166); however, the molecular 
mechanisms of this inhibition are not well understood. Using an established model for 
characterizing the molecular mechanisms of polymerization inhibitors, we offer evidence 
from studies reported herein to support the hypothesis that PrP binds to Aβ fibril ends, 
inhibiting elongation of fibrils. This hypothesis has important implications regarding the 
interaction between PrP and Aβ, and its influence on toxic signaling processes in 
Alzheimer’s disease. 
2.2 Introduction 
 The polymerization of Aβ has been well-described. During polymerization, the 
Aβ peptide self-assembles, starting as an unstructured monomer, adopting a beta-turn-
beta conformation, and growing into long, insoluble fibrils (94,168-171). This process 
can be followed kinetically and data from such studies exhibit a sigmoidal function with a 
lag phase, exponential growth phase, and plateau (172,173). The actual molecular events 
underlying the kinetics are more involved than this simple model suggests; for example, 
the stage of polymerization which features generation of toxic, low molecular weight 
oligomers is yet to be determined. Resolving this issue has become important in the field 
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of Alzheimer’s disease (AD) research, particularly as discovery would address the 
amyloid cascade hypothesis and potentially lead to the development of therapeutics that 
target oligomeric intermediates in the aggregation process.  
 In a study published in 2013, Cohen et al. described a kinetic model to illuminate 
the molecular processes of oligomer formation during Aβ polymerization (100). This 
system was based on an intensive set of theoretical studies of nucleated polymerization 
(172,174,175) designed to shed more light on the influence of  secondary processes  (e.g., 
fragmentation and secondary nucleation); the model was applied in conjunction with 
biochemical assays to show that secondary nucleation processes are central to the 
generation of a small population of soluble Aβ oligomers during polymerization. It was 
hypothesized that a valid therapeutic model for preventing the generation of toxic 
oligomers would be interference of oligomer production through inhibition of the 
secondary nucleation pathway.  
 With this knowledge, it becomes important to discern which molecular processes 
are impacted by specific inhibitors. Several published studies have shown that the kinetic 
model developed by Cohen et al. could be applied to understanding molecular 
mechanisms of chaperones in inhibiting the polymerization of amyloid-forming proteins 
(126,127,176). These chaperones were assigned to several categories that targeted 
specific steps in the polymerization pathway including primary nucleation (127), 
elongation (176), and secondary nucleation (126). Refinement of the model was achieved 
in a 2016 study which incorporated a new set of rate equations designed to determine 
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whether a molecular inhibitor achieved inhibition by binding to monomers, fibril ends, or 
the surface of fibrils (177).  
 PrP has been shown to inhibit Aβ polymerization at sub-stoichiometric 
concentrations (160,166,167). The molecular mechanisms of this inhibitory effect have 
not been previously characterized and some confusion exists regarding the implications 
of the interaction. Although one study offered the observation that PrP could disaggregate 
Aβ fibrils (167), another study refuted this result as an artifact of thioflavin T binding 
(160). It is important to understand the precise nature of this interaction, not only as it 
applies to the potential influence of PrP on local aggregation kinetics of Aβ, but also as a 
means of shedding insight on how PrP and Aβ interact to produce synaptotoxicity. For 
example, some published studies suggest that the N-terminal fragment of PrP may have 
protective effects against oligomer toxicity (155,166,167,178). If the N-terminal domain 
can also inhibit Aβ polymerization, then studies demonstrating this effect may have wider 
implications for the design of therapeutic molecules. 
 We used previously described mathematical modeling (177,179) to determine if 
PrP affects Aβ polymerization kinetics through primary nucleation, elongation, or 
secondary nucleation pathways. To do this, we initially optimized methods to create 
highly reproducible kinetic curves representing Aβ polymerization in the presence and 
absence of PrP; data were fit to determine the appropriate rate constants in the absence of 
PrP.  By varying the individual rate constants for primary nucleation (kn), secondary 
nucleation (k2), and elongation (k+) over a range of PrP concentrations, we were able to 
  
43 
determine the best-fit model for inhibition mechanics. From these data, we developed the 
hypothesis that PrP binds to the ends of growing Aβ fibrils and inhibits their elongation.  
2.3 Methods 
a. Preparation of Aβ monomers 
 Lyophilized Aβ 1-42 was purchased from the ERI Amyloid Laboratory, LLC 
(Oxford, CT, USA). The peptide was solubilized in water and one volumetric equivalent 
of acetonitrile was added as a cryoprotectant before the solubilized peptide was separated 
into 1 mg aliquots; aliquots were lyophilized and stored at -80 °C until required for study.  
For monomer preparation, the peptide was dissolved in 15 mM NaOH to a concentration 
of 1.43 mg/mL as described previously (180). The peptide was sonicated for two hours 
on ice in a benchtop sonicator (Bransonic CPXH, Branson) and centrifuged for 1 minute 
at 20000 x g to remove any remaining insoluble bodies. Monomers were isolated using 
size exclusion chromatography; 500µL of the supernatant was injected onto a Superdex 
75 10/300 GL (GE Healthcare) column and PBS (pH 7.4) was used as the elution buffer.  
Fractions were collected and kept on ice for immediate use in ThT assays or flash frozen 
in liquid nitrogen and stored at -80 °C until needed for EM or binding studies. The 
concentration of Aβ was estimated with a NanoDrop UV-visible spectrometer (Thermo 
Scientific) by reading the sample absorbance at 214 nm and applying Beer’s Law using 
an extinction coefficient (ε) of 76848 M-1cm-1. For seeding assays, Aβ monomers were 
incubated for 16 hrs in PBS at 37 °C, with or without 500 nM PrP. Fibril seeds were 
sonicated on ice for 10 minutes prior to use. 
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b. Circular dichroism (CD) 
 Aβ monomer was prepared using the standard method (Section 2.3, a) and diluted 
to 20 µM in PBS. For CD measurements, the Aβ sample was placed in a quartz cell with 
a 1 mm pathlength. Far-UV data (193-250 nm, 1 nm bandwidth) was collected using a 
Jasco J-815 spectropolarimeter (Jasco Inc.). Raw data (mdeg) was converted to mean 
residue ellipticity (θmrw) using an Mr for Aβ 1-42 of 4514.1 Da. 
Conversion of mdeg to [θ]mrw was performed using the equation: 
[𝜃]𝑚𝑟𝑤 =  
𝑚𝑑𝑒𝑔 × 𝑚𝑟𝑤
10 × 𝑙 × 𝐶
 
where mrw is the mean residue weight calculated for Aβ 1-42 (110.1), l is the pathlength 
in cm, and C is the concentration of Aβ in g/L; for these analyses, l = 0.1 cm and C = 
0.09 g/L (20 µM). 
c. Thioflavin T (ThT) assay for Aβ polymerization 
 Kinetic assays for Aβ polymerization were conducted as described previously 
(179,181).  Briefly, monomers of Aβ were diluted to a concentration of 3 to 10 μM in 
PBS and 10 μM ThT was added from a stock of 1 mM. Recombinant PrP was added from 
a 1 mg/mL stock in water at indicated concentrations. To monitor ThT binding, 100 μL 
samples were added to 96-well, half-volume, low-binding plates (Corning 3881), and 
florescence was read in a Synergy H1 Multi-Mode Microplate Reader (BioTek) every 
two or six minutes at 37 °C (excitation 440 nm, emission 480 nm). Samples used for 
binding studies were removed directly from the wells and transferred to low-binding, 1.5 
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mL tubes, flash frozen, and stored at -80 °C until required for analysis. For the purpose of 
our studies, we used the sigmoidal function: 
𝐹(𝑡) = 𝐹0 +
𝐴
1 + exp (−𝑘 (𝑡 − 𝑡1
2
))
 
to fit polymerization curves and calculate the half time (t1/2), that is the amount of time 
needed for ThT signal to reach half maximum. The half times calculated from this 
method were then represented graphically.  
d. Electron microscopy (EM) 
 To prepare fibrils for imaging, samples of Aβ were centrifuged at 100000 x g in a 
TLA 55 fixed angle rotor (Beckman Coulter) for 30 min. The initial sample volume was 
900 μL; 890 μL of the supernatant was removed before diluting the remaining sample 1:2 
in ultrapure water.  The sample was applied as a 4.5 μL droplet to a glow-discharged, 
300-mesh copper grid and allowed to incubate for 4 minutes before washing 12 times 
with filtered, ultrapure water.  The grid surface was then stained for 1 minute in 2% 
uranyl acetate and dried for 3 minutes. Images were taken using a Philips CM12 120KV 
transmission microscope. Scale bars were added to images, and measurements of fibrils 
were made using ImageJ, with each reported size representing an average of 30 
independent measurements. 
e. Recombinant prion protein (PrP) 
 For details regarding expression and purification of PrP, see section 3.3.f. 
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f. Semi-denaturing detergent agarose gel electrophoresis and capillary transfer 
 Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) of Aβ fibrils 
was performed as described previously (182). The gel was prepared with 1.5% agarose in 
Tris-acetate buffer (25 mM Tris-acetate pH 8.5, 250 mM glycine, 0.1% SDS). Samples 
were not boiled after Laemmli loading buffer was added to avoid further aggregation. 
The gel was electrophoresed for 4 hours at 100 mV and 4 °C in order to achieve the most 
optimal separation of proteins. The samples were capillary-transferred overnight to a 0.2 
μm PVDF membrane in Tris-acetate buffer with 20% MeOH.   Membranes were blocked 
overnight in 3% w/v BSA in TBST before immunoprobing with 6E10 anti-Aβ mouse IgG 
(BioLegend) and anti-mouse IgG (Sigma). 
g. Fluorescence polarization (FP) 
 Fluorescently labeled Hilyte-488 Aβ 1-42 in 1% ammonium hydroxide was 
mixed with unlabeled monomeric Aβ in PBS, pH 7.4 to a final concentration of 25 nM 
labeled and 10 µM unlabeled Aβ. Fluorescence polarization was measured on a Synergy 
H1 Multi-Mode Microplate Reader fitted with a Green FP (485/528) filter cube (BioTek).  
h. Kinetic models of Aβ polymerization 
Mathematical modeling was performed by Ryo Urano, a PhD candidate from the 
laboratory of Prof. John E. Straub (Boston University, Department of Chemistry).  Master 
equations derived by Cohen et al. (179) were used to fit our polymerization curves. For 
the proposed studies, we excluded all variables related to fragmentation of fibrils, as this 
process is attributed to agitation of Aβ during polymerization and all experiments were 
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performed under quiescent conditions. The integrated rate law for the change in 
normalized fibril mass (defined as total mas excluding monomer mass) over time, M(t), is 
represented by: 
𝑀(𝑡)
𝑀(∞)
= 1 − (
𝐵+𝐶+
𝐵+ + 𝐶+𝑒𝜅𝑡
𝐵∓𝐶+𝑒
𝜅𝑡
𝐵∓𝐶+
)
𝑘∞
2
?̃?𝑘∞
𝑒−𝑘∞𝑡 
    (1) 
where  
𝐵± =
𝑘∞ ± 𝑘∞
2𝜅
𝐶± =
±𝜆2
2𝜅2
𝑘∞ = √
2𝜅2
𝑛2(𝑛2 + 1)
+
2𝜆2
𝑛𝑐
𝑘∞  = √𝑘∞2 − 4𝐶+𝐶−𝜅2
 
assuming 𝑀(0) = 0 and the initial concentration of  fibril 𝑃(0) = 0. The model 
parameters can be reduced to two independent degrees of freedom captured by the 
parameters:  
𝜆 = √2𝑚(0)𝑛𝑐𝑘+𝑘𝑛
𝜅 = √2𝑚(0)𝑛2+1𝑘+𝑘2
 
where m(0) is the initial concentration of monomer. The two parameters, 𝜆 and 𝜅, govern 
the individual contributions of the primary and secondary nucleation pathways, 
respectively. 
 In the current experiments, the initial concentration of monomer was held 
constant at 𝑚(0) = 3𝜇𝑀. Previous work (179) suggested that reasonable values of 𝑛𝑐 
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and 𝑛2 would be 2 and these pre-determined values were used in our calculations. Rate 
constants were first determined by global fitting with a Levenberg−Marquardt non-linear 
least-squares algorithm for inhibitor-free conditions. In the global fitting, the function to 
be minimized is defined as:  
𝛥 = ∑ ∑(
𝑡=0𝑛𝑒𝑥𝑝
𝑗
𝑀𝑝𝑟𝑒𝑑,𝑗(𝑡) − 𝑀𝑒𝑥𝑝,𝑗(𝑡))
2 
where 𝑛𝑒𝑥𝑝 defines the number of independent experimental data points for a given 
inhibitor concentration, 𝑀𝑝𝑟𝑒𝑑(𝑡) = 𝑀(𝑡)/𝑀(∞) is obtained from Eq. (1), and 𝑀𝑒𝑥𝑝(𝑡) 
is the similarly normalized experimental value. 
 We first obtained the kinetic rate constants for the inhibitor free condition with 
the initial values of 𝑘+ = 3 × 10
6[1/𝑀𝑠], 𝑘𝑛 = 3 × 10
−4[1/𝑀𝑠], and 𝑘2 = 1 ×
104[1/𝑀2𝑠] as determined from Cohen et. al (179). For finite inhibitor concentrations, 
the global fitting was performed in a systematic manner, changing only a single rate 
constant each iteration while holding other parameters fixed to the inhibitor free values. 
In this way, 𝛥 was independently minimized for datasets representing each inhibitor 
concentration. 
 Stochastic rate constants were defined as 𝑎+, 𝑎2, 𝑎𝑛 for elongation, secondary 
nucleation, and primary nucleation, respectively. Using these constants, kinetic rate 
coefficients for each process were represented by: 
𝑘+,0𝑀(𝑡) = 2𝑎+𝑚(𝑡)𝑃
𝑇𝑜𝑡(𝑡),
𝑘2,0𝑀(𝑡) = 𝑎2𝑚(𝑡)
𝑛2𝑀(𝑡),
𝑘𝑛,0𝑀(𝑡) = 𝑎𝑛𝑚(𝑡)
𝑛𝑐
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To model stochastic chemical kinetics in the presence of an inhibitor, two assumptions 
were required: (1) the existence of a sufficient concentration of inhibitor, stoichiometric 
for each unbound protein; and (2) a faster rate of inhibitor binding compared to the 
production of new unbound molecules with inhibitor binding at equilibrium (177). 
The total concentration of fibrils, 𝑃𝑡𝑜𝑡, included contributions from three species of 
fibrils including inhibitor-free fibrils, 𝑃0; fibrils bound to one inhibitor at one end, 𝑃1; 
and fibrils bound to two inhibitors, one at  each end, 𝑃2. The following formulas result 
when considering the equilibrium constant of the inhibitor binding, 𝐾𝑒𝑞𝐸𝑛𝑑, mass 
conservation, concentrations, and reaction rate: 
𝑃𝑇𝑜𝑡(𝑡) = 𝑃0(𝑡) + 𝑃1(𝑡) + 𝑃2(𝑡)
𝑃2(𝑡) = 𝐾𝑒𝑞𝐸𝑛𝑑𝐶𝑖
𝑇𝑜𝑡𝑃1(𝑡)
𝑃1(𝑡) = 𝐾𝑒𝑞𝐸𝑛𝑑𝐶𝑖
𝑇𝑜𝑡𝑃0(𝑡)
𝑃0(𝑡) =
𝑃𝑇𝑜𝑡(𝑡)
1 + 𝐾𝑒𝑞𝐸𝑛𝑑𝐶𝑖
𝑇𝑜𝑡 + (𝐾𝑒𝑞𝐸𝑛𝑑𝐶𝑖
𝑇𝑜𝑡)2
𝑘+ = 2 ∗ 𝑎+𝑃
0(𝑡) + 𝑎+𝑃
1(𝑡),
 
 where 𝐶𝑖
𝑇𝑜𝑡 is the inhibitor concentration. 
The ratio of the kinetic rate constant for elongation in the presence( 𝑘+) and absence 
(𝑘+, 0𝑀) of inhibitor is:  
𝑘+
𝑘+, 0𝑀
=
2𝑃0(𝑡) + 𝑃1(𝑡)
2𝑃𝑇𝑜𝑡(𝑡)
=
2 + 𝐾𝑒𝑞𝐸𝑛𝑑𝐶𝑖
𝑇𝑜𝑡
2 + 2𝐾𝑒𝑞𝐸𝑛𝑑𝐶𝑖
𝑇𝑜𝑡 + 2(𝐾𝑒𝑞𝐸𝑛𝑑𝐶𝑖
𝑇𝑜𝑡)2
= 𝑓(𝐾𝑒𝑞) 
Assuming independent binding on available protein sites, specific binding of the inhibitor 
to the surface of a fibril results in a Langmuir-type adsorption of the inhibitor to the 
surface. Thus, the amount of deactivated monomer with inhibitor bound, 𝑀𝑏𝑜𝑢𝑛𝑑, is: 
𝑀𝑏𝑜𝑢𝑛𝑑(𝑡) = 𝐾𝑒𝑞𝑆𝑢𝑟𝑓𝐶𝑖
𝑇𝑜𝑡(𝑡) 
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𝑘2 = 𝑎2(𝑀(𝑡) − 𝑀𝑏𝑜𝑢𝑛𝑑(𝑡))𝑚(𝑡)
𝑛2 = (1 − 𝐾𝑒𝑞𝑆𝑢𝑟𝑓𝐶𝑖
𝑇𝑜𝑡)𝑎2𝑀(𝑡)𝑚(𝑡)
𝑛2 
  
= 𝑘2,0𝑀(1 − 𝐾𝑒𝑞𝑆𝑢𝑟𝑓𝐶𝑖
𝑇𝑜𝑡). 
The computational analysis of this set of stochastic equations was performed using R 
(183-186). 
2.4 Results 
a. Preparing Aβ for polymerization studies 
 The preparation of Aβ samples for polymerization reactions was based on 
multiple previous studies, particularly those that focused on rigorous characterization of 
polymerization kinetics using thioflavin T (ThT) fluorescence (179-181).  Two crucial 
steps were reported to influence reproducibility of polymerization, the initial solvent 
conditions and removal of any pre-formed aggregates from solution. Previous studies 
have shown that certain solvents are ideal for promoting a random coil or α-helical 
confirmation of Aβ, which in turn influences the kinetics of polymerization (93,168). In 
addition, a crucial step for reproducibility was the removal of any pre-formed aggregates 
prior to initiation of the polymerization reaction, thereby eliminating variability due to 
early nucleation events (181). For our studies, several solvents and separation methods 
were tested to ensure production of monomeric Aβ that would yield reproducible 
polymerization data.  
 HFIP promotes an α-helical conformation in Aβ and is the standard solvent used 
prior to preparation of synthetic oligomers (110,187). When Aβ from an HFIP film was 
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solubilized in NaOH and sodium phosphate, no detectable monomer was observed by 
size exclusion chromatography (Figure 8, red box, red line); however, a minor aggregate 
peak (Figure 8, blue box, red line) was noted. These data indicated that an HFIP film, in 
addition to being a time-consuming process, was not ideal for initial production of 
monomers. 
 A second, slightly different approach was subsequently investigated; lyophilized 
Aβ peptide was solubilized in 10 mM NaOH without first creating an HFIP film. 
Structural studies of the Aβ peptide have shown that the protein tends to assemble into β-
rich fibrils more quickly when solubilized in NaOH, compared to TFA or HCl (93). After 
the sample was sonicated in an ice bath to break up any residual aggregates, Aβ in NaOH 
was injected into the SEC column. Compared to the HFIP film, this method of 
preparation produced a strong monomer peak (Figure 8, red box, blue line) and evidence 
of incomplete monomerization (Figure 8, blue box, blue line). 
 For comparison, a preparation method that fully denatured the Aβ peptide was 
tested; this procedure simulated initial conditions used for Aβ purified from bacterial 
cultures (181). Aβ peptide was solubilized overnight in 6 M guanidine hydrochloride 
(GdnHCl) prior to analysis by SEC. This preparation method also produced a strong 
monomer peak (Figure 8, red box, green line) without a significant aggregate peak 
(Figure 8, blue box, green line). Of the three methods, use of GdnHCl produced the 
largest amount of monomer compared to aggregated Aβ. However, we sought a method 
that produced adequate levels of monomeric Aβ and lent itself to a streamlined 
experimental approach. As monomer yield was comparable for both the NaOH and 
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GdnHCl methods, and because NaOH had been established as a preparative method 
favoring fibril formation (93), we chose the NaOH solubilization of Aβ peptide. Of note, 
filter methods to isolate monomeric Aβ from pre-formed aggregates (not shown) were 
examined; however, sample loss during the filter process was large and led to adoption of 
SEC as the initial step in preparing Aβ monomers for polymerization experiments.  
 Secondary structure characterization of purified Aβ monomers was performed; 
fractions from the SEC column were collected and analyzed by far-UV circular dichroism 
(CD). SEC purified Aβ monomers exhibited a random coil conformation consistent with 
unstructured peptides (Figure 9, blue curve). Incubation of Aβ at 37 °C over a period of 
24 hrs demonstrated an incremental, but steady structural transition from random coil to 
β-sheet (Figure 9, red (40 min), green (60 min), and purple (24 hrs) curves) consistent 
with the formation of β-sheet-rich fibrils. At 24 hours, most of the Aβ was converted to a 
β-sheet structure.  
b. ThT assay for Aβ polymerization 
 A standard method for monitoring the rate of Aβ polymerization is the use of 
thioflavin T (ThT) as an indicator for the formation of amyloid fibrils. ThT is a 
fluorescent dye with an emission spectrum that is sensitive to its environment; when ThT 
intercalates between amyloid beta-strands, the emission of the fluorophore is slightly red 
shifted and increases significantly in signal strength (188). ThT mixed with purified Aβ 
monomers showed very little change in fluorescence compared to ThT alone (Figure 
10A, red and green curves). However, samples containing ThT and monomers incubated 
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for 16 hours, exhibited a substantial increase in fluorescence with an emission peak at 
480 nm; these data indicated formation of β-rich fibrils (Figure 10A, blue curve).   
 ThT fluorescence monitoring at regular intervals over 16 hrs demonstrated 
characteristic sigmoidal curves with clearly delineated lag (nucleation), exponential 
(growth), and plateau phases; these data were consistently observed for concentrations of 
Aβ between 2 to 10 µM.  At 5 µM, the typical half time for polymerization (time to half 
maximal ThT signal) was 70-90 min (Figure 10B). These kinetic results gave us the 
consistency we needed to repeat and compare multiple conditions in separate 
experiments. 
c. Characterization of fibrils 
 Using negative staining electron microscopy (EM), we observed that monomeric 
Aβ formed fibrils early during the polymerization process; these results were consistent 
with previous reports that fibrils are first detectable during the lag phase (ThT curve 
Figure 11A, EM image Figure 11B) (189,190). During the early exponential phase, the 
fibrils had lengths of 0.5 to 2 μm and displayed a twisted morphology; diameters were 
varied along the length of the fibril, ranging between 4.1 + 0.8 nm in narrow regions and 
12.1 + 1.5 nm in wider areas. At later reaction time points, fibrils tended to clump 
together and their lengths and morphology were more difficult to discern (Figure 11C); 
similar ultrastructural features for Aβ fibrils have been described previously (104,191). 
Only scattered fibrils were observed in the isolated monomer fraction at 0 min and these 
were much more difficult to locate on the EM grid. Generally, fibrils were not detected 
on the surface of the microscopic grid when freshly prepared Aβ was applied (not 
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shown). Most likely, the scattered fibrils that were observed represent a very small 
proportion of the total Aβ present at this time point and are a reflection of how rapidly 
aggregates begin to form after monomers of Aβ are isolated.  
d. PrP inhibition of Aβ polymerization 
 We sought to determine what effect PrP has on the polymerization process itself. 
We found that recombinant PrP profoundly delays Aβ polymerization, even when present 
in amounts that are highly sub-stoichiometric to monomeric Aβ (Figure 12A). The half 
time for polymerization was nearly doubled at a PrP:Aβ ratio of 1:160 (62.5 nM PrP) and 
tripled at a ratio of 1:20 (500 nM PrP) (Figure 12B).  Nevertheless, even in the presence 
of PrP, Aβ polymerization eventually reached a plateau value of ThT binding indicating 
that PrP, at the concentrations examined, slowed, but did not prevent conversion of 
monomeric to fibrillar Aβ.  
 The inhibitory effect of PrP on Aβ fibril formation could also be visualized using 
semi-denaturing detergent agarose gel electrophoresis (SDD-AGE); this technique 
provides a means of separating large, SDS-resistant, amyloid fibrils from monomers and 
smaller aggregates on agarose gels  (182).  After 160 min, Aβ samples polymerized in the 
absence of PrP had reached the plateau phase of ThT binding and contained substantial 
amounts of high molecular weight material, which migrated as a broad smear on the gels 
(Figure 12C, lane 6). At this same time point, Aβ samples polymerized in the presence 
of increasing amounts of PrP contained decreasing amounts of fibrillar material on SDD-
AGE (Figure 12C, lanes 1-5) which corresponded to lower levels of ThT binding.  When 
SDD-AGE analysis was performed at 16 hrs after plateau values of ThT fluorescence had 
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been attained in all samples, there was no apparent difference in the amount of fibrillar 
material between PrP-containing and control reactions (Figure 12D). Again, these results 
indicate that PrP slows, but does not completely prevent fibril formation. 
 We also assessed the effect of PrP on polymerization of fluorescently labeled Aβ 
using fluorescence polarization (FP). In both the presence and absence of PrP, 
polarization increased with time, reflecting incorporation of labeled Aβ monomers into 
fibrils, which have a lower rotational mobility (Figure 13A).  This change in polarization 
was slower in the presence of PrP, consistent with an inhibitory effect on fibril formation 
(Figure 13B).  The FP signal plateaued at a similar value with and without PrP, 
suggesting again that PrP delayed, but did not prevent fibril formation, with all of the 
monomers eventually being converted to fibrillar form. 
e. Seeding experiments 
 When a small amount of pre-formed fibrils is added at the start of an Aβ 
aggregation reaction, the rate-limiting, primary nucleation step is bypassed, shortening 
the lag phase and resulting in rapid formation of new fibrils by secondary nucleation and 
elongation (100). We investigated how PrP affected this process. We seeded a solution of 
5 µM Aβ with a 1% molar equivalent of pre-formed fibrils in the presence and absence of 
PrP, and compared the results to equivalent unseeded reactions. As expected, in the 
absence of PrP, seeding significantly accelerated the polymerization reaction (Figure 
14A, black curve). PrP showed an inhibitory effect in seeded reactions (Figure 14A, 
colored curves), gradually damping the acceleration produced by the seeds. Importantly, 
however, the strength of the effect was reduced when compared to non-seeded reactions 
  
56 
with equivalent amounts of PrP (Figure 14B). For each concentration of PrP, the half 
time was significantly decreased by the addition of seeds (Figure 14C). This result held 
true independent of whether PrP was pre-incubated with the fibrils prior to their addition 
to the reaction (not shown).  
 In another variation of the experiment, we found that fibrils formed in the 
presence of PrP accelerated polymerization reactions to nearly the same extent as fibrils 
formed in the absence of PrP (Figure 15A, green and red curves). The half time for the 
Aβ polymerization reaction was significantly lower than the half time for the non-seeded 
reaction, indicating that the concentration of PrP present in the fibril seeds was 
insufficient to delay polymerization, despite a clear increase in half time when PrP was 
added alone at an equivalent concentration (Figure 15B, Figure 15A, purple curve) 
Taken together, these results suggest that PrP does not have a major effect on the 
secondary nucleation phenomena that occur when reactions are seeded by pre-formed 
fibrils. 
f. PrP inhibits the elongation step of aggregation 
 Given the well-characterized mechanistic features of Aβ polymerization in our 
controlled experimental conditions, we had an opportunity to pinpoint which microscopic 
step(s) were being affected by PrP using a mathematical modeling approach based on the 
macroscopic ThT curves. This strategy has been used successfully to characterize 
interactions between Aβ and several molecular chaperones (177).  We first determined 
the integrated rate law for Aβ aggregation in the absence of PrP, using as a guideline 
published values for the key rate constants (see Section 2.3, h).  We then fit the ThT data 
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from experiments performed in the presence of PrP by systematically varying the rate 
constant for only one of the three molecular steps in the polymerization process: kn for 
primary nucleation, k2 for secondary nucleation, and k+ for elongation.   The best global 
fit to the data was achieved when the elongation rate (k+) was varied in response to PrP 
addition (Figure 16A). The sum of residual errors for this fit was 12, compared to 32.5 
and 35.6 for the fits to variations in kn and k2, respectively (Figures 16B,C). The 
calculated values for k+ exhibited a strong influence of PrP concentration on elongation 
rate, which dropped to 6% of the uninhibited value in the presence of 250 nM PrP, a 1:12 
ratio of PrP to Aβ (Figure 16A, inset; Table 1). 
g. PrP binds to fibril ends 
 Aβ fibrils are thought to grow by monomer addition to the fibril ends 
(100,170,171,192); thus, a plausible explanation for PrP inhibition of Aβ fibril elongation 
is PrP binding specifically to the growing ends of the fibrils and blocking further addition 
of Aβ monomers. If one assumes that PrP is present at sufficient concentrations to bind 
rapidly to Aβ fibrils as soon as the fibrils are generated (i.e., that binding is at 
equilibrium), it is possible to perform a stochastic analysis, in the form of a Langmuir 
binding isotherm, relating the normalized values for k+ to the concentration of PrP (Ci
Tot). 
This expression incorporates an equilibrium constant, Keq, for binding of PrP to the fibril 
ends. The experimentally determined k+ values in the presence of increasing 
concentrations of PrP provide an excellent fit with this model (Figure 16A, inset), 
yielding a Keq of  2.1 x 10
7 M-1 and corresponding dissociation constant of 47.6 nM. This 
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quantitative analysis provides strong evidence that PrP selectively inhibits elongation of 
Aβ fibrils and suggests that it does so by binding tightly and selectively to fibril ends.  
 
2.3 Discussion 
 In Alzheimer’s disease (AD), the polymerization of Aβ from peptide to insoluble 
amyloid fibril is instrumental in producing the neuritic plaques that are a hallmark of the 
disease. This same process has also been hypothesized to produce soluble oligomers that 
are highly toxic to neurons, causing retraction of dendritic spines, loss of synaptic 
function, and excitotoxicity (76,85,98,193-196). One therapeutic approach being 
considered by researchers seeks to disrupt the polymerization process using molecular 
intervention, particularly using chaperone proteins or small molecules that act as 
inhibitors of Aβ self-association (100,124,125,127,197). Another important outcome of 
kinetic studies is a deeper understanding of the protein misfolding and aggregation 
dynamics and their impact on human disease. 
 There are several molecular processes where polymerization inhibitors might 
interfere; primary nucleation, secondary nucleation, and elongation of fibrils. Cohen et al. 
(100) propose that disrupting secondary nucleation is key to preventing the formation of 
toxic soluble oligomers, which are generated through interactions between soluble Aβ 
and fibril surfaces. In a follow-up study (126), the same group identified one such 
inhibitor; the human Brichos domain, which allowed them to test their hypothesis. They 
found that monomeric Aβ polymerized in the presence of Brichos was significantly less 
toxic than Aβ alone. In a similar study, Mansson et al. (127) showed that DNAJB6 
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(another molecular chaperone) displayed potent inhibitory activity that extended the lag 
phase of Aβ polymerization by specifically targeting primary nucleation. While Brichos 
inhibited oligomer production by blocking adsorption of monomers to fibril surfaces, 
DNAJB6 successfully inhibited early nucleation steps necessary for production of Aβ 
oligomers.  
 In the present work, we find that the prion protein (PrP) also acts as a potent 
inhibitor of Aβ polymerization (Figure 12). Applying a kinetic analysis developed in 
previous studies (100,126,177), we demonstrate that, unlike Brichos and DNAJB6, PrP 
achieves an inhibitory effect through interference of fibril elongation (Figure 16). We 
support this model with biochemical studies showing that PrP does not prevent the 
secondary nucleation that occurs when polymerization reactions are seeded with pre-
formed Aβ fibrils (Figure 14). In comparison to published data on chaperone molecules, 
our kinetic profiles produced when PrP is added during Aβ polymerization most closely 
resemble inhibition of fibrillization of the yeast prion protein, Ure3, by Ssa1p in a process 
determined to occur through blocking of fibril elongation (176). Further, we show that 
changes in the rate constant for elongation (k+) in the presence of PrP were consistent 
with binding of PrP to fibril ends (Figure 16A, inset), also consistent with modeling for 
Ssa1p. 
 If we examine the model of Aβ polymerization. (Figure 7), PrP does not fit into 
the scheme of potential therapeutic inhibitors as it does not prevent nucleation processes 
from producing new soluble oligomers from the available pool of Aβ monomers. 
However, it is worth revisiting this model to consider the feedback loop established for 
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secondary nucleation. It is reasonable to propose that slowing elongation results in a 
growing pool of soluble oligomers, both from failed incorporation of oligomers into 
fibrils and continuation of fibril surface interactions which produce new nuclei. In this 
case, we have a testable hypothesis that adding PrP to the polymerization reaction could 
actually increase the soluble oligomer pool. In this case, PrP could contribute to toxicity 
indirectly by increasing the ratio of toxic soluble oligomers compared to relatively inert 
fibrils. This would be consistent with studies showing that disruption of endogenous PrP 
expression rescues behavioral deficits and early mortality in select Alzheimer’s disease 
transgenic models (153).  
 Alternatively, it may also be reasonable to assume that the interactions that inhibit 
elongation do not have significant physiological impact on Aβ oligomer toxicity. PrP has 
been shown to bind with higher affinity to Aβ oligomers compared to monomers or 
fibrils (84,158). In a cellular environment, PrP may not have an opportunity to impact 
fibril growth, particularly if it binds with high affinity to soluble oligomers, likely to be 
locally accessible to cell membrane proteins like PrP due to diffusion. In addition, the 
observation that the N-terminal domain of PrP has a protective effect in the presence of 
Aβ oligomers (155,178) is more consistent with the idea that N1 is able to sequester and 
block oligomers from interaction with PrP on the cell surface. To shed light on this 
subject, the binding relationship between PrP and Aβ aggregates must be investigated 
further.  
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Figure 8. Preparation of Aβ monomers for polymerization experiments. 
Aβ1-42 peptide was prepared using several methods and monomers were purified using 
size exclusion chromatography (SEC). The blue line on the chromatograph shows results 
for Aβ solubilization in NaOH. Specifically, 1 mg of lyophilized Aβ 1-42 was dissolved 
in 700 µL of 15 mM NaOH, sonicated on ice for two hours, centrifuged for 15 minutes at 
20000 x g to remove insoluble aggregates, and 500 µL of the sample injected on a 
Superdex 57 10/300 GL column (total protein mass, 0.7 mg); the elution buffer was 50 
mM phosphate, pH 7.4. Alternatively, lyophilized Aβ peptide was dissolved in HFIP and 
dried under a steady nitrogen stream to a thin film which formed at the bottom of a glass 
vial. The film was solubilized in 10 mM NaOH and diluted with 10 mM sodium 
phosphate buffer to a concentration of 100 µM; 0.5 mL of this sample was analyzed by 
SEC (total protein mass, 0.23 mg) and represented by the red line. The green line 
illustrates SEC results from Aβ solubilized in GdnHCl at a concentration of 1 mg/mL for 
22 hours prior to analysis; 0.5 mL (total protein mass, 0.5 mg) of sample was 
chromatographed.  Arrows indicate elution volume (Ve) for molecular weight standards. 
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Figure 9. Structural characterization of Aβ by far-UV circular dichroism. 
Aβ monomer was prepared by solubilizing lyophilized Aβ in 15 mM NaOH and isolating 
the monomer fractions by SEC. Monomers were diluted to 20 µM in PBS, pH 7.4. 
Sample was incubated at 37 °C, placed in a quartz cuvette with a 1 mm pathlength, and 
scanned in the wavelength range from 193-250 nm for secondary structural analyses. 
Freshly prepared monomer lacked secondary structure (blue line, 0 min), but over a 24 
hrs time interval adopted a β-sheet structure characteristic of amyloid fibrils (red, 40 min; 
green, 60 min; and purple, 24 hrs). Spectra are shown only to 200 nm due to high noise 
introduced by the salt concentration of the sample.  
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Figure 10. Thioflavin T assay for Aβ polymerization. 
(A) Thioflavin T (ThT) emission spectra for 10 µM ThT alone (green curve) or 
combined with an equimolar amount of Aβ monomers (red curve) or fibrils (blue curve) 
in 50 mM sodium phosphate buffer, 300 mM NaCl, pH 7.4. Fibrils were formed by 
incubating purified monomers for 24 hours at 37 °C. (B) ThT curves produced during Aβ 
polymerization. Aβ monomers were diluted to 5 µM in PBS pH 7.4 and 100 µL samples 
were added to a 96-well low-binding half-volume plate. The plate was incubated in a 
Synergy H1 reader at 37 °C without shaking. Data were collected at 6 minute intervals; 
excitation and emission wavelengths were 430 and 480 nm, respectively. Colors 
represent individual polymerization experiments; conditions in each reaction were 
identical. Baseline (ThT without Aβ present) was subtracted, and data was normalized to 
maximum ThT signal. 
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Figure 11. Electron microscopy of Aβ fibrils. 
(A) ThT curve for an Aβ polymerization reaction. ThT fluorescence was recorded in a 
plate reader analyzed in parallel with samples that were incubated in the same 96-well 
plate without ThT. Samples were removed from the plate and flash frozen at the times 
indicated by red crosses on the polymerization curve, t = 38 and 970 min. (B) Electron 
microscopy (EM) with negative staining for fibrils isolated during the exponential growth 
phase of polymerization (red crosses on ThT curve). Fibrils were generally long (0.5 to 2 
µm) and displayed a twisted morphology with alternation fibril diameters ranging 
between 4.1 + 0.8 nm and 12.1 + 1.5 nm. (C) EM results for fibrils produced after 16 hrs 
incubation at 37 °C in the plate reader. Fibrils were shorter, 0.1 to 0.5 µm in length, and 
of uniform width averaging approximately 8 nm (7.3 + 1.3 nm).  
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Figure 12. PrP inhibits Aβ polymerization at sub-stoichiometric ratios compared to 
monomeric Aβ. 
(A) ThT curves for polymerization of Aβ (10 µM) in the presence of increasing 
concentrations of PrP. Arrows indicate the approximate time points (t = 160 and 858 min) 
at which samples were removed for the SDD-AGE transfers shown in panels C and D 
(samples for C were taken from another experiment, not shown but with similar lag 
times). (B)  Effect of PrP on the half times for Aβ polymerization, taken from the curves 
in panel A. Markers represent three replicates. Error bars are present but not visible due 
to low variation (+ 1-2 min). (C,D)  SDD-AGE analysis of Aβ samples in the presence of 
varying amounts of PrP. Samples were polymerized for 160 min (C) or 16 hrs (D).  PrP 
concentrations for C were 500 nM (lane 1), 250 nM (lane 2), 125 nM (lane 3), 62.5 nM 
(lane 4), 31.2 nm (lane 5), and 0 nM (lane 6). PrP concentrations for D were: 500 nM 
(lane 1), 250 nM (lane 2), 125 nM (lane 3), 62.5 nM (lane 4), and 0 nM (lane 5). Blots of 
the gels were probed with anti-Aβ antibody 6E10. The migration of 10 kDa and 200 kDa 
molecular size markers is indicated, as are the positions of Aβ monomers, small 
aggregates, and fibrils. 
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Figure 13. Evidence that PrP inhibits Aβ polymerization from fluorescence 
polarization analyses. 
(A) Fluorescence polarization curves for polymerization of Aβ (10 µM) with the addition 
of 25 nM Hilyte-488 –labeled Aβ and increasing concentrations of PrP. (B) Summary of 
half times determined from curves in A. 
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Figure 14. PrP does not prevent secondary nucleation by pre-formed fibrils. 
(A) ThT curves for the seeded polymerization of Aβ (5 µM) in the presence of PrP. 
Seeding was achieved by the addition of pre-formed Aβ fibrils to the reaction at 0 min; 
fibril concentration was equivalent to 1% monomer. The black, dashed line shows 
unseeded polymerization without PrP. (B) ThT curves for the unseeded polymerization of 
Aβ (5 µM) in the presence of increasing concentrations of PrP. (C) Effect of PrP on the 
half times for Aβ polymerization in the seeded and unseeded conditions, from the data in 
panels A and B. Markers represent three replicates. Error bars are present, but not visible 
due to low variation (+ 1-2 min). 
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Figure 15. Fibrils produced in the presence of PrP retain seeding capability. 
(A) Polymerization of Aβ (5 µM) was seeded by the addition of 10% monomer-
equivalent of fibrils formed in the presence (green line) or absence (red line) of 500 nM 
PrP. Unseeded control reactions contained no PrP (dotted black line), or 50 nM PrP 
(purple line), which is the amount that would be carried over by addition of 10% seeds 
formed with 500 nM PrP. (B) Half times of polymerization were calculated from the 
curves in panel A. Markers represent three replicates. Error bars are present, but not 
visible due to low variation (+ 1-2 min). 
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Figure 16. PrP selectively inhibits fibril elongation. 
(A) ThT polymerization curves for 3 µM Aβ in the absence of PrP (beige), and in the 
presence of the following concentrations of PrP: 7.8 nM (yellow), 15.6 nM (green), 31.3 
nM (purple), 62.5 nM (blue), 125 nM (orange), and 250 nM (teal). The solid lines show 
best global fits to the data based on varying the kinetic constants for (A) elongation rate, 
k+; (B) secondary nucleation rate, k2; or (C) primary nucleation rate, kn. The cartoons in 
each panel illustrate the step in the polymerization process at which PrP (denoted by P) is 
assumed to act. (D) Fit for the rate constant k+ variance with increasing concentration of 
PrP. The solid line gives the equilibrium constant Keq = 2.1 x 10
7 M-1. Raw values for rate 
constants are shown in Table 1. 
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Table 1. Average experimental values and fits derived from varying the elongation 
(k+), secondary nucleation (k2), and primary nucleation (kn) rate constants. 
 
Inhibitor k+ (raw) kn (raw) kn (raw) k+ (scaled) k2 (scaled) kn (scaled) 
250 nM 1.4e+05 3.5e-04 1.5e-10 5.9e-02 5.2e-08 3.7e-07 
125 nM 4.7e+05 1.9e+02 1.1e-06 2.0e-01 2.9e-02 2.7e-03 
62.5 nM 9.4e+05 1.4e+03 1.9e-05 3.9e-01 2.1e-01 4.7e-02 
31.3 nM 1.8e+06 4.3e+03 1.7e-04 7.6e-01 6.5e-01 4.3e-01 
15.6 nM 1.8e+06 4.5e+03 1.8e-04 7.7e-01 6.8e-01 4.6e-01 
7.8 nM 1.8e+06 4.3e+03 1.8e-04 7.6e-01 6.5e-01 4.6e-01 
0 nM 2.4e+06 6.7e+03 4.0e-04 1.0e+00 1.0e+00 1.0e+00 
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CHAPTER THREE: THE C-TERMINAL DOMAIN OF THE PRION PROTEIN 
PLAYS AN ESSENTIAL ROLE IN AMYLOID-BETA BINDING AND 
POLYMERIZATION INHIBITION 
3.1 Summary 
 It is well established that the cellular prion protein (PrP) is one type of receptor 
for amyloid-beta (Aβ) oligomers and binding interactions between the two have been 
linked to neurotoxic signaling. However, data characterizing the interaction between PrP 
and other species of Aβ, particularly amyloid fibrils is scarce. We have shown previously 
through mathematical analysis of the polymerization kinetics of Aβ that PrP binds 
specifically to the ends of Aβ fibrils at a nanomolar affinity. Here, we support this 
observation with multiple complementary binding studies showing that PrP has a high 
affinity for both Aβ oligomers and fibrils. We also demonstrate that low affinity binding 
between PrP and Aβ monomers is dependent on the PrP C-terminal domain, a region also 
necessary for polymerization inhibition. This insight offers a better understanding of how 
PrP interacts with neurotoxic species of Aβ.  
3.2 Introduction 
 The presence of soluble Aβ oligomers in the Alzheimer’s disease (AD) brain is 
strongly linked to progression of neurodegeneration (71,72,74,98). This observation has 
led to the hypothesis that small, soluble oligomers of Aβ are key contributors to disease 
pathology, potentially through toxic interactions with cell surface receptors (69). In 2009, 
Lauren et al. identified the cellular prion protein (PrP) as a receptor for Aβ oligomers; 
binding resulted in PrP expression-dependent suppression of long-term potentiation in 
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neurons (84). In follow-up studies, Um et al. probed the mechanisms of oligomer 
toxicity, showing activation of Fyn kinase pathways through a direct interaction between 
PrP and mGluR5 initiated by Aβ oligomer binding (86,161). These studies and others 
have linked the PrP-Aβ oligomer interaction with dendritic spine retraction, as well as 
behavioral and pathological changes in mouse models of AD (86,153,161,198).  
 The affinity of PrP for Aβ oligomers is quite high. Lauren et al. reported a range 
of Kd values from 50-100 nM based on Aβ monomeric concentration to 0.4 nM when 
actual concentration of oligomer was considered (84). Chen et al. published a Kd of 
approximately 70 nM calculated from EPR studies (154), and Frier et al. described a Kd 
of 80-100 nM, again based on monomer concentration (78). In contrast, all three studies 
reported non-detectable monomer binding at low micromolar concentrations. Fewer 
studies have examined binding interactions between PrP and Aβ fibrils. Nicoll et al. 
showed that synthetic Aβ oligomers assemble into protofibrils 20-200 nm in length, and 
that PrP has a higher affinity for these protofibrils than for oligomers (158). Nieznanski et 
al. reported binding of PrP to Aβ fibrils that were formed through polymerization of 
purified monomeric Aβ (160). This report refuted earlier studies from the same group that 
contended that PrP bound only to soluble oligomers (154). 
 We have shown that PrP inhibits Aβ monomer polymerization, specifically 
through binding to the ends of Aβ fibrils, and that this binding to fibrils occurs with 
nanomolar affinity (Chapter 2). From our model, we estimate a Kd based on monomer 
equivalent of about 50 nM, which is consistent with Kd reported for oligomers. In order 
to provide support for this observation, we followed up our polymerization studies with 
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multiple complementary binding assays to directly compare binding between PrP and 
monomers, fibrils, and oligomers of Aβ. We show that PrP binds to all three forms of Aβ 
in a rank order of binding strengths, i.e. PrP affinity for Aβ fibrils > oligomers > 
monomers. We also show that the inhibition of Aβ polymerization by PrP appears to be 
dependent on the presence of the PrP C-terminal domain, which in turn can be linked to 
the protein’s affinity for both fibrils and monomers. These observations give us a more 
detailed understanding of the complex interaction between PrP and Aβ. In addition to 
advancing our knowledge of the polymerization kinetics of Aβ, these structural insights 
suggest new approaches to clarifying the interactions between PrP and toxic species of 
Aβ.   
3.3 Methods 
a. Preparing Aβ for polymerization and binding studies 
 For Aβ polymerization studies, monomeric Aβ was prepared as described in 
section 2.3.a. ADDLs were generated using a standard protocol (110,199) in which 
lyophilized Aβ peptide was solubilized in HFIP and dried to a film under a steady stream 
of nitrogen gas. The film was then solubilized in DMSO before dilution to a 
concentration of 100 μM in Ham’s F12 phenol-red-free medium (total v/v DMSO 2%), 
followed by incubation at room temperature for 16 hrs. ADDL preparations were 
characterized by SEC; 500 µL of sample (0.23 mg total protein mass) was injected into a 
Superdex 75 10/300 GL column and PBS, pH 7.4 was used as the elution buffer. 
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b. Electron microscopy (EM) 
 Electron microscopy with negative staining was performed as described 
previously (section 2.3.d) with the exception that ADDLs were not centrifuged prior to 
application of the sample onto the carbon grid. 
c. Surface plasmon resonance (SPR) 
 SPR was performed using the ProteOn XPR36 protein interaction array system 
(BioRad) as described previously (155). 9E10 anti-cMyc antibody (Invitrogen) was 
immobilized on a ProteOn GLM sensor chip using the standard protocol for amine 
coupling. PrP 23-230-cMyc (ligand) was captured on the surface, followed by an analyte 
flow step with Aβ monomers, fibrils, or ADDLs; the injection period was 240 s with a 
flow rate of 50 μL/min.  Non-specific binding interactions between Aβ and the 9E10 
antibody were subtracted from the sensorgram using the ProteOn analysis software. 
d. Dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) 
 To coat 96-well DELFIA yellow plates (PerkinElmer), PrP was diluted to 500 nM 
in 20 mM MOPS, pH 7.4 and 50 μL samples were added to each well.  The plate was 
incubated for one hour at 37 °C while shaking at 400 rpm on a Thermomixer R incubator 
(Eppendorf); the wells were subsequently washed five times with 300 μL TBS, 0.05% 
Tween-20 (TBST). Plates were blocked for one hour 37 °C with 0.1 % BSA in TBST, 
followed by another wash step. ADDLs were diluted in PBS, 50 μL was added to each 
well, and the plate was incubated at 400 rpm for one hour at 25 °C, and then washed. For 
Aβ time points, each time point was diluted in PBS, and 50 μL was added to each well 
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before incubating the plate at 25 °C for 10 minutes.  Plates were washed and anti-Aβ 
antibody 6E10, diluted in DELFIA assay buffer (PerkinElmer), was added at a 
concentration of 1 μg/mL to each well; plates were incubated at 25 °C for one hour, 
followed by another wash. Secondary antibody (DELFIA Eu-N1 anti-mouse IgG, 
PerkinElmer) was added at a concentration of 0.3 µg/mL to each well and plates 
incubated at 25 °C for one hour. Subsequently, plates were washed, DELFIA 
enhancement solution (PerkinElmer) was added at 100 μL per well, and a last incubation 
at 25 °C for 15 minutes was performed prior to measurement of time resolved 
fluorescence in a Synergy H1 Multi-Mode Microplate Reader (BioTek) (excitation and 
emission wavelengths were 320 and 615 nm, respectively with a 100 ns delay).   
e. Fluorescence polarization (FP) 
 To prepare fluorescently labeled PrP 23-109, Alexa Fluor 488 C5 maleimide 
(ThermoFisher Scientific) was dissolved in water at a stock concentration of 1 mM. 
Lyophilized 23-109-cys was dissolved in 20 mM MOPS, pH 7.4 and 0.5 mM TCEP to a 
concentration of 100 μM, and Alexa Fluor 488 was added dropwise with stirring; the 
final protein to fluorophore volume ratio was 1:1, and final concentrations of PrP 23-109-
cys and Alexa Fluor 488 were 50 μM and 500 μM, respectively. This solution was 
protected from light and allowed to incubate at room temperature for two hours on a 
benchtop rotator. After 2 hrs, 1 mL of the solution was injected into an analytical C3 
column (Zorbax 300SB C3, Agilent) on an Agilent 1200 Infinity HPLC system and the 
peptide peak was collected and lyophilized. Confirmation of Alexa Fluor labelled protein 
was made by MALDI-TOF mass spectrometry. 
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 To perform fluorescence polarization experiments, fluorescently labeled PrP 23-
109 was mixed with Aβ samples in PBS. Fluorescent polarization was measured on a 
Synergy H1 Multi-Mode Microplate Reader fitted with a Green FP (485/528) filter cube 
(BioTek). Polarization values were calculated using the Synergy Gen 5 software 
(BioTek). 
f. Recombinant prion protein (PrP) 
 Full length murine PrP (23-230) and 23-109-cys sequences were synthesized by 
ATUM/DNA 2.0 (Newark, CA) in the vectors, pJ414 and pJ411, respectively, using E. 
coli-optimized codons. PrP 23-119, 23-144, 23-230-c-Myc, and 110-230 were generated 
by site-directed mutagenesis using appropriate primers with PrP 23-230 as the template. 
PrP 110-230 was expressed with a 5’ 6-histadine tag and TEV protease cleavage site; the 
sequence for the histadine tag was MRGSHHHHHHGENLYFQG. The 3’ c-Myc tag 
sequence for 23-230-c-Myc was EQKLISEEDL. Linker constructs S4 (PrP 105 to 125 
converted to the sequence GGGGSGGGGSGGGGSGGGGS), S5 
(GGGSGGGSGGGSGGGSGGGS), and SG10 (SGSGSGSGSGSGSGSGSGSG) were 
generously supplied by Graham Roseman, a graduate student in the laboratory of Prof. 
Glenn L. Millhauser, UC Santa Cruz.  All DNA constructs were sub-cloned into the 
pET101 TOPO vector (Invitrogen Grand Island, NY) using the Champion pET101 
Directional TOPO expression kit (Invitrogen). The ligation product was transformed into 
TOP10 chemically competent E. coli (Invitrogen) and incubated at 37 °C overnight on 
LB plates with ampicillin. Colonies were selected and sequenced using a T7 forward 
primer. The sequenced DNA was then transformed into BL21 Star E. coli (Invitrogen) for 
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protein expression. A single BL21 Star colony was chosen and used to grow glycerol 
stocks for each construct, which were stored at -80 °C until required for experimentation. 
 Glycerol stocks were thawed briefly and grown in 25 mL LB medium for 5 hours 
at 37 °C with shaking at 350 rpm prior to transfer into autoinduction medium (200); cells 
were allowed to grow overnight under the same conditions. The cell pellet was isolated 
by centrifugation at 5000 rpm (4785 x g) at 4 °C for 30 min in a JLA-8 rotor (Beckman 
Coulter) and resuspended in lysis buffer (0.1 M Tris HCl, 0.1 M NaOAc, pH 8.0 5 mM 
EDTA, 1 tablet cOmplete Protease Inhibitor Cocktail (Roche)). Cells were gently lysed 
by two passages through a French press, and soluble and insoluble fractions were 
separated by centrifuging lysed cells for 30 min at 12500 rpm (11290 x g) at 4 °C in a 
JA-20 rotor (Beckman Coulter). Purification proceeded as described previously (130) 
with some modifications to the protocol detailed in the next paragraph.  
 PrP 23-230, 23-230-c-Myc, ∆105-125, S4, S5, and SG10 were all isolated in 
inclusion bodies in the insoluble fraction of the cell lysate. In order to purify the inclusion 
bodies, the insoluble fraction was resuspended in 0.1 M Tris HCl, 0.1 M NaOAc, pH 8.0 
and 5 mM EDTA, 2 M amberlite-treated Urea, 2% (v/v) Triton X-100; the remaining 
insoluble fraction was centrifuged at 20000 rpm (31360 x g) at 4 °C in a JA-20 rotor. 
This step was repeated twice with Urea, EDTA, and Triton X-100 omitted from the wash 
buffer in the 2nd iteration. Inclusion bodies were then extracted by resuspending the pellet 
in 8 M GdnHCl, 0.1 M TrisHCl, 0.1 M NaOAc, pH 8.0 and spinning down any remaining 
insoluble material at 20000 rpm (31360 x g) for 1 hr at 4 °C in the JA-20 rotor. All 
constructs were then purified on an ÄKTA FPLC system (GE Healthcare) using 70 mL of 
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sepherose resin packed into an XK 26/20 column and prepared with 0.2 M Ni2+ for 
immobilized metal affinity chromatography (IMAC). Proteins were loaded onto the 
column in 8M urea, 0.1 M NaOAc, 0.1 M TrisHCL pH 8.0; buffer was mixed with 
ultrapure water via a constant gradient over 3 column volumes to 10% v/v before 
washing off loosely bound proteins with 50 mM imidazole in 10% loading buffer. Protein 
was eluted from the Ni2+ immobilized metal ion affinity column with 5 M GdnHCl , 0.1 
M NaOAc, 0.1 M TrisHCL, 0.1 M potassium phosphate (pH 4.5) while monitoring 
absorbance (A280). Fractions spanning the elution peak were collected and combined; the 
pH of the eluted sample was raised to 8.0 by titration with potassium acetate and the 
protein was allowed to oxidize and refold overnight at 4 °C.    
 The N-terminal constructs, PrP 23-119 and 23-144, were expressed in the soluble 
fraction of the cell lysate. For isolation of these proteins, no inclusion body purification 
steps were required; samples were applied directly to the Ni2 using the loading buffer, 0.1 
M Tris HCl, 0.1 M NaOAc, pH 8.0. All other steps for IMAC purification were identical. 
For the construct, PrP 23-109-cys, 1 mM TCEP was added to all Ni2+ buffers to prevent 
oxidation of the C-terminal cysteine.  
 All constructs, with the exception of PrP 110-230, were desalted using a HiPrep 
26/10 desalting column (GE Healthcare), exchanged into 20 mM potassium acetate, pH 
5.5, and purified by reverse-phase HPLC using a C4 column (Grace/Vydac). Fractions 
containing the purified protein were pooled, lyophilized, and stored at -80 °C until 
needed. Protein stocks were reconstituted in 0.2-μm filtered water and quantified using a 
NanoDrop UV-visible spectrometer (Thermo Scientific) prior to study.   
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 For PrP110-230, inclusion bodies were prepared as described above, and the 
loading buffer used for IMAC was identical. Refolding was performed overnight in an 
on-column procedure by gradual buffer exchange to 50 mM NaOAc, 50 mM TrisHCl, pH 
8.0, 40 mM imidazole, followed by a 10 column volume wash. Elution buffer was 500 
mM imidazole, 50 mM NaOAc, 50 mM Tris, pH 8.0. The eluate was desalted into 20 
mM Tris, 20 mM KOAc, pH 8.0 and 0.1 mg of TEV protease was added.  Enzymatic 
cleavage was allowed to proceed overnight at 4 °C.  The TEV protease and uncleaved 
protein was removed the following day with Ni2+ resin; the remaining protein was 
concentrated, purified using the Superdex 75 10/300 GL column in 20 mM Tris, 20 mM 
KOAc, pH 8.0 and flash frozen in this buffer, and stored at -80 °C.   
 For PrP110-230, inclusion bodies were prepared as described above, and loading 
buffer for IMAC was identical. Refolding was performed overnight on-column by 
gradual buffer exchange to 50 mM NaOAc, 50 mM TrisHCl pH 8.0, 40 mM imidazole, 
followed by a 10 column volume wash. Elution buffer was 500 mM imidazole, 50 mM 
NaOAc, 50 mM Tris pH 8.0.  The elution was desalted into 20 mM Tris, 20 mM KOAc 
pH 8.0 and 0.1 mg of TEV protease was added. Enzymatic cleavage was allowed to 
proceed overnight at 4 °C.  The TEV protease and uncleaved protein was removed the 
following day by polishing with Ni2+ resin, and the remaining protein was concentrated 
and purified using the Superdex 75 10/300 GL column in 20 mM Tris, 20 mM KOAc pH 
8.0.  The protein was flash frozen in this buffer and stored at -80 °C until use.   
g. Thioflavin T (ThT) assay for Aβ polymerization 
 ThT assays were performed as described in section 2.3.c  
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 3.4 Results 
a. Preparation of oligomers for binding studies 
 As a starting point for binding experiments, we produced synthetic Aβ oligomers 
of a type that has been used frequently and reported in the literature, particularly in 
toxicity studies involving PrP (86,153,161,198). These oligomers are referred to as 
amyloid-beta derived diffusible ligands (ADDLs) (201). ADDLs have been characterized 
as heterodisperse globular structures, with estimated size ranging from 20 to 100 
monomers (84,154,201). Unlike monomeric Aβ, ADDLs are resistant to fibril formation. 
This makes them well-suited to cell toxicity or in vivo assays; it also provides us with the 
opportunity to compare binding of three distinct phases of Aβ assemblages; i.e. SEC-
purified monomers, fully characterized fibrils, and stable, soluble oligomers.  
 To keep our oligomer preparation consistent with those used for toxicity studies, 
we used the standard protocol for making ADDLs (201), and several methods to 
characterize the resulting oligomers. In keeping with earlier preparation protocols, we 
analyzed each separate preparation of ADDLs by injecting the sample into a size 
exclusion column (SEC). From the Superdex 75 10/300 GL column, ADDLs eluted in the 
void volume of the column, indicating a Mr  >100 kDa (Figure 17A); this is consistent 
with an aggregate composed of ≤ 20 Aβ monomers. Imaging with negative stain electron 
microscopy showed a collection of globular aggregates 5 to 10 nm in diameter (Figure 
17B). These observations, along with toxicity assays performed in the Harris Laboratory 
(not covered in this work), were sufficient to convince us that we were able to reproduce 
ADDLs consistent with those used in published studies. 
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b. Full length PrP binds monomers, fibrils, and oligomers of Aβ  
 To compare binding of PrP to monomers, fibrils, and oligomers of Aβ, we 
employed three different techniques: surface plasmon resonance (SPR), dissociation-
enhanced lanthanide fluorescence immunoassay (DELFIA), and fluorescence polarization 
(FP). 
 For SPR experiments, we created recombinant PrP with a c-Myc epitope located 
at the C-terminus of the protein and captured it on the SPR chip using 9E10 antibody. 
This strategy was adopted in order to leave the N-terminal domain of PrP, containing the 
two putative Aβ binding sites, free to interact with Aβ that was perfused over the chip in 
the mobile phase.  We compared the binding of Aβ samples to PrP at 0 min and 16 hr, 
time points representing mainly monomer and fully polymerized fibrils, respectively. Our 
data demonstrated that the 0-min sample displayed detectable binding (~180 RUs after 
240 secs of perfusion) only at the highest concentration of Aβ (15 µM) (Figure 18A).  
The 16-hr sample gave much larger responses, ranging from 180-700 RUs over an Aβ 
concentration span of 0.9-15 µM (Figure 18B); these results presumably reflect the 
larger molecular weight of fibrils compared to monomers. As a control, the binding of an  
ADDLs preparation to PrP was tested and results were consistent with those previously 
published (155) (Figure 18C). Taken together, these data demonstrate that PrP binds 
efficiently to fully polymerized Aβ fibrils and to ADDLs. Moreover, PrP displays a much 
weaker affinity for Aβ monomers, although the much smaller mass of monomers 
compared to fibrils makes binding of the monomeric form more difficult to detect. It was 
not possible to calculate reliable dissociation constants for the PrP-Aβ binding reaction 
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from these SPR data due to the fact that binding of the analyte (Aβ) did not reach 
saturation during the injection phase.  These anomalies of PrP-Aβ interactions in SPR 
experiments have been noted in a previous study (202). 
 We used DELFIA to assess PrP-Aβ interactions under equilibrium conditions. Aβ 
samples were incubated in polystyrene wells containing immobilized PrP, and the amount 
of bound Aβ was measured using anti-Aβ antibody 6E10. We observed binding of 
monomers (0 min, both fresh and frozen), fibrils (16 hr) and ADDLs; apparent 
dissociation constants for fibrils and ADDLs were 1.072 + 0.339 µM and 0.105 ± 0.035 
µM, respectively (Figure 19). A dissociation constant for monomers was not determined 
because Aβ binding did not reach saturation or near-saturation at the tested 
concentrations. The actual Kd values for fibrils and ADDLs are likely to be much lower 
than the apparent values due to the fact that the molar concentrations of these forms are 
only a fraction of the molar concentration of Aβ monomer. For example, using estimates 
from Lauren et al. regarding average oligomer size, our binding constant of 0.105 µM 
could be as low as 0.4 nM, which is in agreement with their data (84). Results from these 
studies confirm that, while PrP binds Aβ monomers, fibrils and ADDLs, the protein has a 
higher affinity for fibrillar and oligomeric forms of Aβ.  
 Both SPR and DELFIA are surface-based binding techniques with limitations; 
these analyses may be subject to artifacts resulting from non-specific interactions that 
interfere with the ability of PrP to bind Aβ. Therefore, we tested PrP-Aβ binding using 
fluorescence polarization (FP), a technique based on the free rotation of fluorescently 
labeled molecules in solution. To produce a suitably small probe, we used an N-terminal 
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fragment of PrP (residues 23-109), which encompasses two previously identified binding 
regions for Aβ aggregates (84,202). PrP 23-109 was expressed with a free cysteine 
residue at the C-terminal end of the protein that could be labeled with AlexaFluor-488 C5 
maleimide (Figure 20A). To test the capability of our PrP N-terminal probe to register 
changes in rotational state on binding to Aβ oligomers in solution, we performed a 
binding experiment with ADDLs. In this experiment, a polarization shift consistent with 
saturated binding was observed (Figure 20B). We then compared the change in 
polarization measured in samples collected at different time points during an Aβ 
polymerization reaction; our assumption was that, during this time interval, an evolution 
of Aβ from monomeric to fibrillar form would occur. The 0-min sample (monomer) did 
not exhibit a polarization shift, as expected for a small peptide (Figure 20C, blue line). 
Samples with equivalent Aβ concentrations taken at 24 min (lag phase; Figure 20C, red 
line), 48 min (early exponential phase; Figure 20C, green line) and 90 min (plateau 
phase; Figure 20C, purple line) produced progressively greater shifts. 
 These results demonstrate that PrP 23-109 binds to Aβ fibrils that form during the 
polymerization process. The Kd value for PrP-fibril binding (calculated from the 90 min 
curve) was 1.25 + 0.064 µM, a value comparable to the DELFIA result (1.072 + 0.339 
µM). The Kd for PrP-ADDLs obtained from the FP analysis, on the other hand, was much 
higher than the value calculated from the DELFIA study, 3.66 + 0.35 µM vs. 0.105 ± 
0.035 µM. This can be explained by the heterogeneity of the sample; fluorescence 
polarization is an average of all bound ligands and ADDLs are a heterodisperse collection 
of aggregates ranging in size from 20 to 100 Aβ monomers (201).  
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 Although there is no significant shift in polarization observed for the Aβ 0 min 
sample, the data do not necessarily indicate a lack of binding to monomers or to small 
aggregates (dimer, trimers), as these assemblies would be too small to produce a 
measurable shift in FP values. This is supported by the fact that an even larger ligand, 
anti-PrP antibody (Mr = 150,000), did not cause a shift in polarization (Figure 20D). 
However, consistent with both our SPR and DELFIA data, FP results support the 
hypothesis that PrP binds with high affinity to fibrils produced during the course of Aβ 
polymerization.  
c. The C-terminal domain of PrP affects binding to monomeric Aβ  
 It has been shown previously that the unstructured N-terminal domain of PrP 
contains two polybasic regions (residues 23-27 and 95-110) essential for binding to 
ADDLs, while the globular C-terminal domain is not required for this function (Figure 
21A, upper schematic) (84,202). Using a dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA), we tested the roles of the N- and C-terminal domains of PrP in 
binding of the protein to monomers and fibrils of Aβ. Figure 21A shows schematic 
diagrams of the deletion constructs used for experiments described in section 3.4.c-e. All 
constructs were purified separately as detailed in section 3.3.e, and assessed for purity by 
both SDS-PAGE gel (Figure 21B) and western blotting. 
 Two N-terminal domain constructs (PrP 23-119 and 23-144), as well as an 
internally deleted construct missing the central region (PrP Δ105-125), displayed 
relatively unimpaired affinity for Aβ fibrils (Figure 22A). In contrast, the C-terminal 
domain construct PrP 110-230, which is missing both N-terminal Aβ-binding domains, 
  
94 
exhibited significantly reduced binding to Aβ fibrils.  These results imply that Aβ fibril 
binding, analogous to interactions with ADDLs, depends primarily on sites in the N-
terminal domain of PrP.  
 We then used DELFIA to test the ability of the same PrP constructs to bind to Aβ 
monomers. We found that the C-terminally deleted construct PrP 23-119 displayed a 
greatly reduced ability to bind to Aβ monomers (Figure 22B), despite an affinity for Aβ 
fibrils that was comparable to full length PrP (Figure 22A). The PrP 23-144 construct 
displayed slightly reduced monomer binding. These surprising results suggested that the 
C-terminal domain of PrP (particularly residues 120-144) plays a role in binding to 
monomeric Aβ even though this region is not essential for binding to Aβ fibrils.  
d. The C-terminal domain is required for Aβ polymerization inhibition  
 Next, we tested the ability of our constructs to inhibit the growth of Aβ fibrils. 
Based on binding studies, we expected all constructs with similar binding affinities for 
fibrils to inhibit Aβ polymerization. Not surprisingly, removing the entire N-terminal 
domain with the two Aβ binding regions (PrP 110-230), completely abolished the 
inhibitory effect of PrP on Aβ polymerization (Figure 23A vs. Figure 23B). 
Unpredictably, however, we found that the isolated N-terminal domain (23-119) of PrP, 
which binds both ADDLs and fibrils, also had no effect on Aβ polymerization (Figure 
23C). The more C-terminally extended construct, PrP 23-144, which is truncated just 
before the first α-helix, had a weak inhibitory effect at the highest concentrations that was 
much less than full length PrP (23-230) (Figure 23D). Taken together, these results 
imply that both the N-terminal and C-terminal domains are required for PrP to efficiently 
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inhibit Aβ fibril elongation; more importantly, it appears that ability of PrP to bind Aβ 
monomers may be linked to its inhibitory effect. 
e. The central region of PrP plays a role in the inhibition of Aβ polymerization 
 Our results show that PrP 23-144 does not inhibit Aβ polymerization to the same 
extent as PrP 23-230 (Figure 23D). We have also observed that 23-144 has a decreased 
affinity for monomeric Aβ (Figure 22B). This observation led us to hypothesize that the 
region containing residues 120-144 plays a critical role in inhibition of the Aβ 
polymerization process. We tested PrP ∆105-125, a deletion mutant of PrP that produces 
a neurotoxic phenotype in mice, for its ability to inhibit Aβ polymerization. We found 
that ∆105-125 inhibited polymerization less effectively than the full length protein, 
implying that the deleted central region is important for inhibitory activity (Figure 24A).  
 To test whether the size of the ∆105-125 construct was influencing inhibition 
effectiveness, we generated three mutant constructs, all of which replaced the central 
region residues 105-125 with flexible linkers containing glycine and serine. We 
compared the inhibitory effect of each of these constructs with ∆105-125. Each construct 
displayed a reduced ability to inhibit aggregation compared to PrP 23-230 (Figure 24B-
D). These observations conflict with the hypothesis that steric hindrance alone is 
sufficient for inhibition of polymerization; the residues in the deleted 105-125 region 
must also play a role. 
 When Aβ polymerization reaction half times at 500 nM PrP were compared, a 
trend emerged in which PrP 23-230 had the greatest inhibitory effect, followed by ∆105-
125 and the linker constructs, then 23-144; this pattern was consistent for all 
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concentrations of PrP, but was most apparent at 500 nM (Figure 25). PrP 23-119 and 
110-230 have no impact on Aβ polymerization, despite the fact that 23-119 binds to Aβ 
fibrils. These data appear to be consistent with the hypothesis that PrP must display both 
fibril binding affinity, dependent on the N-terminal binding sites, as well as monomer 
binding affinity, dependent on the 120-144 region, to fully inhibit Aβ polymerization. 
3.5 Discussion 
 The role that PrP plays in Aβ toxicity is not yet fully understood, but it is known 
that PrP binds to Aβ, with a particular affinity for Aβ oligomers (84,154). Previous 
studies have neglected characterization of the interactions between PrP and Aβ non-
oligomeric aggregates; however, this is in part due to the fact that Aβ oligomers are 
considered the relevant neurotoxic aggregates based on prior studies (85,97,98,128). 
Overlooking other Aβ aggregate species may be unwise for two important reasons. First, 
PrP binding of Aβ fibrils may impact access of oligomers to PrP binding sites, 
particularly if the interaction is of high enough affinity to out-compete the smaller Aβ 
aggregates. Second, Aβ structural studies indicate some common themes in conformation 
between soluble oligomers and fibrils (203), implying that a better understanding of how 
PrP interacts with one Aβ form could potentially inform the other.  
 In the previous chapter of this thesis, we showed that PrP inhibits Aβ 
polymerization through binding to Aβ fibril ends, with an estimated dissociation constant 
of about 50 nM. In order to explore this observation further, we turned to several 
complementary binding assays to compare the affinity of PrP for monomers, fibrils, and 
oligomers of Aβ. Using surface plasmon resonance (SPR), a technique for detecting 
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binding of analyte to bound surface protein by local changes in mass, we were able to 
observe interaction of PrP with all three Aβ species including freshly purified monomers, 
fibrils, and oligomers (ADDLs) (Figure 18). Because we were unable to reach true 
equilibrium with SPR, we also employed a dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA), a highly sensitive technique for detecting binding at 
equilibrium. Using this method, we directly compared the binding of PrP to Aβ and 
estimated Kd for interactions of PrP with ADDLs and fibrils; the estimated Kd for ADDLs 
was 105 nM, consistent with previously reported values (84), and the estimated Kd for 
fibrils was 1.07 µM (Figure 19). Finally, we used fluorescence polarization to measure 
binding of PrP to ADDLs and fibrils, showing that the polarization shift for fluorescently 
tagged PrP 23-109 reached saturation only after Aβ had reached the plateau phase of 
aggregation (Figure 20). This assay gave us another consistent measurement of Kd for 
fibrils, approximately 1.25 µM; although the estimated Kd for ADDLs was much higher, 
this result was most likely due to the heterogeneity of radii in the molecular assemblies 
contained in the sample.  
 Although the fibril dissociation constant differed by an order of magnitude from 
that for ADDLs, both Kd values were determined based on pre-aggregate monomer 
concentration. ADDL size has been estimated to range from 20 to 100 monomers 
(84,154,201), while fibrils are much larger aggregates. We estimate fibrils contain a 
monomer equivalent of at least ten times that of oligomers, which means our binding 
constant could easily reflect a higher affinity for fibrils than for ADDLs. These results are 
consistent with the literature. Both Nieznanski et al. and Nicoll et al. have established the 
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groundwork for fibril binding studies, although neither group has characterized  binding 
affinities (158,160). In addition, we used a method for synthesizing Aβ fibrils that is 
distinct from the previous investigations. Our fibril formation method was based on 
carefully controlled kinetic studies with temporal characterization of Aβ polymerization 
by ThT binding for a maximum of 16 hours; previous studies produced fibrils using 
alternative techniques (82,154,155). The data we generated from the described 
experiments are both novel and built upon interactions suggested in previous studies. 
 An interesting outcome of combining robust polymerization assays with binding 
studies is the observation that PrP-Aβ fibril interactions are not the sole determinate of 
polymerization inhibition. We compared the binding of several different PrP deletion 
mutants to monomeric and fibrillar forms of Aβ, and found that the N-terminal domain of 
PrP, which contains previously identified binding sites for Aβ oligomers (154,155), binds 
to fibrils but not to monomers (Figure 22). Only when residues 120-144 are incorporated 
into the construct does PrP begin to display binding to monomers, and then only at a 
fraction of the affinity of the full length protein. These results have a surprising 
correlation with the ability of PrP constructs to inhibit polymerization; the effect is only 
observed when the C-terminal domain is present, and decreases when the central region 
(105-125) is deleted or replaced with a flexible linker (Figure 25). 
 According to recent structural studies, Aβ monomers bind to the filament ends of 
the growing fibrils, initially through hydrogen bonding of residues accessible in the β-
strand (94). Early monomeric interactions represent docking events in Aβ fibril 
elongation. The stability of binding between monomer and fibril is highly dependent on 
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the proper sequence orientation for establishment of in-register hydrogen bonds (170); 
without the correct hydrogen bond formation, the monomer will eventually dissociate. 
Given these observations, we propose a two-step process for inhibition of Aβ 
polymerization by PrP. First, the N-terminal domain of PrP binds to Aβ at or near the end 
of a growing fibril. Second, the C-terminal domain of PrP prevents additional Aβ 
monomers from binding to the Aβ fibril end in proper orientation with the correct 
hydrogen bonds to lock into the growing filament; the result of this latter process is 
monomer dissociation. The proposed mechanism could be attributed to two causes:  1) 
steric hindrance from the C-terminal domain of PrP once the protein is bound at the Aβ 
fibril end, or 2) more specific interactions that require Aβ monomer binding, potentially 
combined with steric hindrance from PrP.  
 The hypothesis that steric hindrance alone drives inhibition of Aβ polymerization 
is not supported by data from experiments with constructs that feature PrP central region 
sequences replaced by a flexible linker (S4, S5, and SG10); these proteins exhibited the 
same decreased inhibitory effect as PrP ∆105-125. Instead, we argue that our results 
support the second model in which PrP binding to Aβ fibril ends, as well as cooperative 
low affinity binding to Aβ monomers, prevents successful docking of additional Aβ 
monomers to the fibrils, thereby inhibiting elongation. The 120-144 region of PrP does 
not allow the N-terminal deletion mutant (110-230) to bind strongly to monomeric Aβ on 
its own; however, it is clear that this region of PrP increases the binding affinity of the 
protein for Aβ monomers when incorporated into the C-terminal deletion mutant (Figure 
22B, 23-119 vs. 23-144). In our proposed model, the PrP region containing residues 120-
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144 could be responsible for driving the association of the protein with Aβ monomers. 
The presence of this region would allow the C-terminal domain of PrP to interact with 
freshly bound Aβ monomers at the filament ends, preventing proper docking. Although 
in need of further validation, our hypothesis offers an interesting perspective on the 
biophysical mechanisms that may control the interactions between Aβ and PrP. 
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Figure 17. Characterization of Aβ oligomers (ADDLs). 
ADDLs were prepared according to the standard protocol outlined in Klein et al. (201) 
(A) SEC of ADDLs on a Superdex 75 10/300 GL column, showing a peak in the void 
volume, indicating elution of globular proteins of Mr > 100 kDa. Black arrows indicate 
elution volumes of individual molecular weight standards. (B) Electron micrograph (EM) 
of negatively stained ADDLs showing small globular aggregates.  
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Figure 18. Comparison of Aβ binding to PrP using surface plasmon resonance 
(SPR). 
PrP with a C-terminal c-Myc tag was captured on the surface of a GLM chip using anti-
cMyc antibody 9E10. Aβ, at the indicated concentrations, was perfused over the chip for 
240 secs; the chip was then washed with buffer (PBST). Sensorgrams show binding in 
resonance units (RU) for (A) monomeric, (B) fibrillar (polymerized for 16 hrs), and (C) 
oligomeric (ADDLs) forms of Aβ. 
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Figure 19. Comparison of Aβ binding to PrP using dissociation-enhanced lanthanide 
fluorescence immunoassay (DELFIA). 
PrP was incubated on polystyrene plates for one hour before blocking and applying Aβ. 
Curves show binding of the indicated concentrations (monomer-equivalents) of Aβ 
monomers, before (red curve) and after (green curve) flash freezing; Aβ fibrils 
(polymerized for 16 hrs, purple curve), and Aβ oligomers (ADDLs) (blue curve). 
Estimated Kd values for fibrils and ADDLs were 1.072 + 0.339 µM and 0.105 + 0.035 
µM, respectively. 
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Figure 20. Comparison of Aβ binding to PrP using fluorescence polarization (FP). 
(A) Diagram for AlexaFluor-488-labeled PrP 23-109 used as a probe in fluorescence 
polarization experiments. (B) Fluorescence polarization of 25 nM AlexaFluor-488-
labeled PrP 23-109 with increasing concentrations of ADDLs. (C) FP of labeled PrP 23-
109 with increasing concentrations of Aβ over a time course from 0-90 min following 
initiation of polymerization. Shown are data from samples at reaction initiation (0 min, 
blue); mid-lag phase (24 min, red); exponential phase (48 min, green); and plateau 
phase (90 min, purple) based on thioflavin T kinetic assays (not shown). (D) 
Fluorescence polarization of labeled PrP 23-109 with increasing concentrations of anti-
PrP antibody. 
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Figure 21. PrP constructs for binding and inhibition studies. 
(A) Diagram for constructs used in the binding and polymerization experiments are 
represented. The two Aβ binding sites are indicated on the 23-230 construct. OR, 
octapeptide repeats; CR, central region linker (residues 105-125); and H1-H3, three α-
helices in the structured C-terminal domain. (B) SDS-PAGE of all constructs. 
Immunoprobing with appropriate antibodies (not shown) confirmed purity and 
biochemical nature of samples; upper bands represent minor amounts of aggregated PrP 
and lower bands are natural cleavage products of the protein. 
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Figure 22. Deletion of the C-terminal domain of PrP has little effect on its binding to 
Aβ fibrils, but reduces its binding to Aβ monomers.   
Binding of the indicated concentrations (monomer-equivalents) of (A) Aβ fibrils 
(polymerized for 16 hrs) and (B) Aβ monomers was analyzed by DELFIA. PrP constructs 
fixed to the plates were full length PrP (23-230) (blue), N-terminal deletion mutant 110-
230 (red), C-terminal deletion mutants 23-119 (green) and 23-144 (purple), and central 
region deletion mutant ∆105-125 (orange). 
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Figure 23. The C-terminal domain of PrP is required for inhibition of Aβ 
polymerization. 
ThT curves for polymerization of Aβ (5 µM) in the presence of increasing concentrations 
of PrP (A) 23-230, (B) 110-230, (C) 23-119, and (D) 23-144. Each curve represents the 
average of triplicate samples; polymerization for each construct was repeated three times 
and representative curves shown. 
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Figure 24. Deletion of the central region of PrP reduces inhibition of Aβ 
polymerization. 
A) ThT curves for polymerization of Aβ (5 µM) in the presence of increasing 
concentrations of PrP ∆105-125. (B-D) Constructs were created to replace the central 
region (105-125) with a flexible serine/glycine linker. Linkers tested included (B) S4, a 
4X repeat of GGGGS; (C) S5, a 5X repeat of GGGS; and (D) SG10, a 10X repeat of SG. 
None of these constructs restored the inhibitory effect observed with PrP 23-230. 
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Figure 25. Inhibition of Aβ polymerization by deletion mutants of PrP. 
Reaction half times for Aβ (5 µM) polymerization in the presence of each indicated PrP 
construct (from Figures 23 and 24) are expressed as ratios and represented graphically. 
Markers represent 3 replicates of three reactions for each construct, with standard error. 
At a concentration of 500 nM, PrP 23-230 causes a three-fold increase in the half time of 
the Aβ polymerization reaction. In contrast, the deletion mutant ∆105-125 and its 
corresponding linker constructs S4, S4, and SG10, cause a two-fold increase. The C-
terminal and N-terminal deletion mutants have minimal influence on the half time of 
polymerization. 
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CHAPTER FOUR: CONCLUSIONS 
4.1 Overview 
 The major findings of this dissertation work are as follows:  1) the prion protein 
(PrP) inhibits amyloid-beta (Aβ) polymerization by binding with high affinity to the ends 
of Aβ filaments and preventing Aβ fibril elongation, and 2) the N- and C-terminal 
domains of PrP work cooperatively to bind to monomers of Aβ and prevent Aβ fibril 
elongation through this cooperative interaction. 
 Previous studies have shown that PrP inhibits Aβ aggregation, but the molecular 
mechanisms of this effect have not been characterized. Using carefully controlled 
conditions, we produced typical sigmoidal curves for the Aβ polymerization reaction and 
characterized the fibrillar types of Aβ that formed during the process. When PrP was 
added to the Aβ polymerization reaction, half times were significantly delayed at a 
PrP:Aβ ratio as low as 1:160. The inhibitory effect of PrP was not eliminated by seeding 
polymerization with pre-formed fibrils of Aβ, but lag times indicated that PrP was unable 
to block secondary nucleation of Aβ catalyzed by seeding interactions on the fibril 
surface. We created curve fits for reaction rate constants based on Aβ polymerization in 
the absence of PrP; when the reaction was studied in the presence of PrP, changes in the 
Aβ fibril elongation rate constant were observed and these were consistent with specific 
inhibition of fibril growth by PrP. Our data from further characterization of the 
polymerization process indicated the occurrence of a specific, high affinity binding 
interaction between PrP and the ends of Aβ fibrils. 
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 The exact size and structure of toxic Aβ oligomers is still undetermined; however, 
specific binding of PrP to Aβ oligomers has long been the assumption regarding 
synaptotoxic interactions between the two proteins. We performed complementary 
binding studies using surface plasmon resonance (SPR), dissociation enhanced lanthanide 
fluorescence immunoassay (DELFIA), and fluorescence polarization (FP) to investigate 
PrP interactions with different forms of Aβ. Our data showed that PrP exhibits weak 
association with Aβ monomers, but binds with high affinity to Aβ oligomers and fibrils. 
 We tested a series of PrP deletion mutants to explore the relationship between 
binding affinity to Aβ and inhibition of Aβ polymerization. We found that all PrP 
constructs bound to Aβ fibrils with similar affinity, with the exception of the N-
terminally deleted construct, PrP 110-230. However, we were surprised to discover that 
PrP binding to Aβ monomers was strongest when the C-terminal domain of PrP was 
present. In Aβ polymerization reaction studies, monomer binding appeared to be 
consistent with the ability of PrP to inhibit Aβ fibril elongation. Deletion of the central 
region of PrP resulted in less inhibition of Aβ polymerization and this effect was not 
restored when the central region of PrP was replaced with a linker. From these 
observations, we conclude that a previously uncharacterized site in the C-terminal 
domain of PrP acts in a cooperative manner with the N-terminal binding sites to promote 
interaction of PrP with Aβ monomers; furthermore, these cooperative binding 
interactions are essential for inhibition of Aβ polymerization. 
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4.2 Size matters 
 While there is general acceptance of the amyloid cascade hypothesis, areas that 
currently lack consensus include accurate identification of the toxic forms of Aβ and 
specific delineation of the mechanism by which these structures are formed. Numerous 
studies have established a link between soluble oligomers of Aβ and synaptotoxicity, but 
characterization of the toxic oligomers is wide ranging from dimers to large, globular 
aggregates > 100 kDa in size (76,83,108,109). This broad spectrum of oligomeric 
structures is observed in both synthetic Aβ preparations, as well as water-soluble 
preparations from AD brain. Binding studies implicating PrP as a toxic receptor for Aβ 
oligomers show a similarly wide range of toxic species, depending on the preparative 
method and experimental paradigm (78,83,84,158). 
 One of our initial goals in undertaking this work was to narrow down the list of 
possible Aβ oligomer binding partners for PrP. This was in part based on previous studies 
showing that Aβ bound to the N-terminal domain construct, PrP 23-111, in a time-
dependent manner with highest binding signal produced after 4 hours of incubation at 37 
°C (155). However, in our binding studies, we found that PrP interacts with Aβ 
monomers and fibrils, although with different binding affinities. Most striking was the 
interaction between PrP and Aβ fibrils, predicted in several previous studies but not fully 
characterized. While disappointing in terms of using the PrP-Aβ interaction to define 
toxic species, these data were consistent with previous reports indicating PrP’s lack of 
specificity for any one Aβ species. 
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 When testing the binding of full length PrP to Aβ, we saw little specificity of PrP 
for any one size of Aβ aggregate. However, differences in binding were noted when PrP 
deletion mutants were analyzed. We found that deletion of the C-terminal domain 
significantly impacted the ability of PrP to bind to monomers of Aβ, as did deletion of the 
N-terminal domain. Together, these results support the hypothesis that the C- and N-
terminal domains of PrP are required for cooperative binding to Aβ. 
4.3 Inhibition of Aβ polymerization 
 Chaperones or chaperone-like molecules have been proposed as potential 
therapeutic approaches in pathologies linked to the amyloid cascade hypothesis. It has 
been proposed that the inhibitory effect of PrP on Aβ polymerization is highly relevant in 
this model (167). Our kinetic reaction curve fits for PrP inhibition of Aβ polymerization, 
mathematically derived from the kinetic rate constants (100) reveal that PrP interacts with 
the ends of Aβ filaments and prevents fibril elongation (Figure 26). 
 Molecular chaperones that inhibit either the primary or secondary nucleation 
phases of Aβ polymerization may ameliorate the damaging effects of Aβ toxicity. The 
rationale for inhibition of primary nucleation is clear; preventing toxic aggregates from 
forming at initiation of the process would likely be an effective strategy. This tactic is 
consistent with the AD therapeutic approach of reducing secretase activity. Alternatively, 
inhibition of secondary nucleation is a more complex strategy, but preliminary testing has 
yielded positive results in preventing toxicity (126). It has been proposed that inhibition 
of secondary nucleation processes should slow Aβ oligomer production, normally 
occurring on the fibril surfaces. However, our data suggests that PrP is not an appropriate 
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chaperone for therapeutic intervention. Preventing elongation of Aβ fibrils does not 
address either the formation of Aβ oligomers through primary nucleation, which occurs 
earlier in polymerization, or the accessibility of Aβ fibril surfaces for the production of 
new oligomers through secondary nucleation.   
 Another potential protective mechanism that has been proposed for rescue of 
toxicity through the Aβ polymerization pathway has been the use of small molecules to 
promote the aggregation of Aβ into insoluble fibrils; this strategy is founded on the 
hypothesis that Aβ fibrils are not sources of the toxic signal (128). Based on this 
argument, it is possible that PrP can actually enhance toxic effects by binding to toxic 
small filaments or molecular assemblies of Aβ and preventing the incorporation of these 
structures into more mature fibrils. While this approach is consistent with data from 
toxicity studies, it would be difficult to measure the degree of PrP-dependent toxicity 
specifically attributed to this effect; our suspicion is that the result would be minor. 
However, we do feel confident in our assessment that PrP is not a candidate for 
therapeutic targeting of the Aβ polymerization pathway. 
4.4 Model for Aβ-PrP interactions 
 We have explored the effect of various deletion mutants on the ability of PrP to 
bind fibrils and monomers of Aβ, and to inhibit the polymerization of Aβ. One of the 
most striking results from our studies was that the two previously identified binding 
regions for Aβ on the flexible N-terminal domain of PrP were not sufficient to inhibit Aβ 
polymerization (Figure 27). Instead, there appeared to be a correlation between the 
presence of the structured PrP C-terminal domain and the inhibitory effect of the protein, 
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a surprising result because interactions between the C-terminal domain of PrP and Aβ 
have not yet been described. However, the C-terminal domain of PrP alone did not bind 
to Aβ fibrils with high affinity, and had no effect on Aβ polymerization. In addition, 
when central region residues (105-125) were deleted, PrP showed a decrease in inhibitory 
effectiveness compared to PrP 23-230. This change was not restored when the central 
region was replaced with serine/glycine linker chains. On examination, there appeared to 
be a connection between the presence of the region containing residues 120-144 and Aβ 
monomer binding. PrP residues 120-144 do not facilitate binding of the N-terminal 
deletion mutant to Aβ, but do markedly increase binding of the C-terminal deletion 
mutant; these findings imply cooperativity between this C-terminal region and the 
flexible N-terminal domain in the binding of PrP to Aβ monomers. 
 Simulated and experimental studies of the Aβ fibril formation process have 
produced a model of filament elongation where monomers of Aβ first bind to free 
filament ends, subsequently assume a transitional conformation, and finally ‘lock’ into 
the structure of the filament (94,170,171,192). This locking effect has been reported to be 
dependent on binding of the ensuing Aβ monomer, a description based on kinetic models 
(171). Rojas et al. recently conducted simulation studies of unstructured Aβ monomer 
binding to a fibril template to show that the locking step is reliant on the ability of the 
monomer to find the correct hydrogen bonds; if a new Aβ monomer does not dock 
correctly onto the filament end, it will dissociate (170). 
 We propose a model in which PrP blocks Aβ filament elongation by binding to 
the ends of growing filaments and positioning its C-terminal domain in such a way as to 
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sterically block docking of new Aβ monomers. Based on the mechanisms proposed by 
Rojas et al. and other investigators, even mild disruption of the correct hydrogen bond 
orientation for an incoming monomer of Aβ (caused by a shift of less than one amino 
acid residue) could be enough to prevent the protein from docking correctly on the fibril 
(170). In our model, we propose that PrP blocks the addition of monomeric Aβ to fibrils 
by creating an environment in which the monomers dock incorrectly, dissociate, and 
thereby slow the elongation of Aβ fibrils.  
 The significance of the 120-144 region of PrP in this model is twofold. First, this 
region of the protein contains a stretch of hydrophobic residues known as the 
hydrophobic core (150), which gives PrP a strong potential to interact with hydrophobic 
ends on exposed Aβ filament β-strands. Second, a naturally occurring mutation in human 
PrP (Y125Stop) produces the equivalent of the recombinant protein PrP 23-144; this 
mutation causes Gerstmann-Sträussler-Scheinker (GSS)-like symptoms and features 
extensive PrP amyloid deposits in the brain (204). Studies of this PrP construct have 
shown that the protein has a critical core of residues, 112-139, that form β-sheet-rich 
fibrils capable of seeding conformational changes in native PrP (205). We propose that 
this hydrophobic core has a high likelihood of being able to interact with exposed β-
strands at the ends of Aβ filaments. Though the binding of the flexible N-terminal 
domain of PrP to Aβ fibrils would theoretically allow the bulky C-terminal domain of 
PrP to orient in a number of ways, we propose that the hydrophobic core of PrP drives 
specific interactions with the filament ends that are related to its affinity for Aβ 
monomers docked on the surface. In this model, the C-terminal domain of PrP would 
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wrap over the end of the Aβ fibril and create steric hindrance to prevent new Aβ 
monomers from binding to and elongating the fibril. The deletion of PrP residues 105-
125 disrupts this interaction and lowers the likelihood that the C-terminus of the protein 
is in the correct position at the end of the Aβ filament; this scenario explains why 
replacing the PrP residues with a flexible linker did not fully restore the inhibitory effect 
compared with PrP 23-230. Our proposed model as it relates to the secondary structure of 
PrP is shown in Figure 28. 
4.5 Implications for toxicity 
 Data from our studies, which show that binding between Aβ fibrils and PrP 
occurs with high affinity, adds to the growing amount of literature addressing the 
question of the specific role of Aβ oligomers in synaptotoxicity. As we have pointed out, 
our results are consistent with previous studies, in which fibrils have been shown to be 
toxic, although only by cell death assays (93-95), which lack the elegant approaches used 
in analysis of Aβ oligomers. Of the previous studies showing fibril toxicity, Petkova et al. 
perhaps make the best case for variation in results based on the initial conditions used in 
fibril preparation (95). It is possible that a common mechanism of binding holds true for 
both Aβ oligomers and certain fibrillar forms of Aβ, in which case our data are novel in 
portraying a new detail in the PrP-Aβ interaction, which requires the cooperation of the 
structured C-terminal domain of PrP. Although we have not performed toxicity studies on 
Aβ samples prepared for the experiments reported in this dissertation research, such 
analyses would be informative and likely strengthen our characterization of the PrP-Aβ 
interaction. It is interesting to note that experiments using the N-terminal cleavage 
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product of PrP showed a protective effect; the corresponding observation that PrP 23-119 
preferentially binds Aβ fibrils would seem to favor fibril toxicity. 
4.6 Future directions 
 We have proposed a model for PrP-Aβ interactions that relies heavily on the PrP 
hydrophobic core region, 111-134. Our work with PrP central region deletion mutants 
addressed the contributions of more than 50% of the residues in this domain, but we were 
unable to demonstrate a complete abolishment of the inhibitory effect of PrP on Aβ 
polymerization with any of the proteins. Thus, based on our model, we would 
hypothesize that a deletion mutation encompassing the entire region (PrP ∆111-134) 
would significantly diminish inhibition compared to PrP 23-230. These studies should be 
straight forward and could lead to a more targeted investigation of the biophysical 
interactions between PrP and Aβ. 
 We have not extensively discussed the issue of Aβ toxicity in relation to our 
results; the connection between these in vitro studies and toxicity is unclear. We could 
propose, based on our observations, that cooperative interactions between the N- and-C-
terminal domains of PrP could be significant to the physiological interactions between 
Aβ and PrP, particularly those that drive toxicity. First, it would be important to establish 
whether the Aβ preparation method used in our studies produces toxic species. 
Subsequently, the relationship between PrP C-terminal interactions and toxicity should be 
tested; these investigations could be performed with a deletion mutant similar to the one 
we would use for testing PrP inhibition of Aβ polymerization, i.e. PrP ∆111-134. 
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 In conclusion, collectively, the data from this dissertation research present proxy 
evidence for PrP binding specifically to Aβ fibril ends. However, our results do not 
present direct evidence for this proposed mechanism. Imaging studies are underway to 
determine more conclusively whether PrP binds specifically to Aβ fibril ends early in the 
polymerization process. 
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Figure 26. Model for PrP inhibition of Aβ polymerization. 
Polymerization model based on Cohen et al. showing the stepwise Aβ polymerization 
process with our proposed mechanism for PrP inhibition of Aβ fibril elongation. Red 
arrows indicate steps at which therapeutic inhibitors are hypothesized to be most 
effective. 
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Figure 27. Summary of observed interactions between PrP and Aβ. 
Diagrams of full length PrP (23-230) and deletion mutants; a summary of mutant effects 
in the biophysical assays described in the text is included on the right side of the panel. In 
the PrP diagrams, green checked regions are Aβ binding domains as established by Chen 
et al. and Fluharty et al. (154,155);  red regions labeled HC are the hydrophobic core 
described by Aguzzi et al. (150); H1-3, α-helices; and OR, octapeptide repeat. In the 
table on the right, In.= inhibition of Aβ polymerization; M.B.= Aβ monomer binding; 
F.B.= Aβ fibril binding. “High” is used to describe the level of inhibition and binding as 
compared to observed values for PrP 23-230.    
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Figure 28. Proposed model of interaction. 
Full length PrP shown with a summary of active regions in the proposed mechanism by 
which PrP binds to Aβ fibril ends and blocks polymerization. The flexible N-terminal 
domain of PrP contains both regions necessary for Aβ binding. The hydrophobic core is 
the site of the novel binding interaction proposed in this dissertation and supports low-
affinity, cooperative binding of PrP to Aβ monomers at Aβ filament ends. The structured 
C-terminal region of PrP sterically hinders Aβ monomer binding to filament ends thereby 
inhibiting Aβ fibril growth. Nomenclature as in Figure 26. 
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APPENDIX: A CENTRAL REGION DELETION MUTANT OF PRION 
PROTEIN DOES NOT CREATE PORES IN NEUTRAL CHARGE LIPID 
BILAYERS 
 The normal functions of the cellular prion protein (PrP) have not yet been fully 
characterized. In transgenic mice, knockout of both PrP gene loci does not yield a distinct 
phenotype (131). However, several deletion mutants of the protein, including a central 
region mutant that eliminates residues 105-125 ( PrP ∆CR), result in neurodegenerative 
phenotypes (206). Deletion of nine residues at the N-terminus of PrP rescued this 
phenotype (207). Patch clamping experiments with PrP ∆CR showed spontaneous ion 
currents in HEK293 cells (208). These currents were characterized as non-selective, and 
were similar to currents produced by pore-forming cytolytic toxins. This observation led 
to the hypothesis implicated spontaneous currents in the toxic mechanism by which PrP 
∆CR induced neurodegeneration (209). Two potential explanations for the currents were 
proposed; PrP ∆CR 1) forms pores in the cell membranes through interaction with cell 
surfaces via a penetrative property of the nine-residue sequence at the N-terminal end of 
the protein (Figure 29) or 2) interacts with cell surface receptors, either directly or 
indirectly, causing abnormal channel activity in the cells. 
 We designed a set of experiments to test the idea that PrP ∆CR created pores in 
the cell membrane lipid bilayer through interactions at the cell surface. Using a 
freeze/thaw and extrusion process, we produced liposomes using 10 mg POPC 
(phosphatidylcholine), a neutrally charged lipid common in cell membranes (13.16 mM) 
and 120 μg PDP-PE (phosphatidylethanolamine), a polar lipid with a functionalized head 
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group (131.6 μM). Liposomes prepared in this manner were approximately 100 nM in 
diameter (Figure 30). Both full length and ∆CR forms of PrP were expressed with a C-
terminal cysteine (WT-cys and ∆CR-cys, respectively) to facilitate linkage to maleimide-
functionalized PDP-PE and purified by immobilized metal affinity chromatography 
(Figure 31). Successful linkage was confirmed by separating the liposomes using 
differential ultracentrifugation and detecting PrP in the liposome layers of the sucrose 
gradient (Figure 32).  
 PrP-bearing liposomes were tested in two separate assays to determine if pores 
were forming in the membrane. First, we performed a dye release assay using the 
ANTS/DPX dye-quencher pair. Within the liposome, collisional quenching between the 
two molecules keeps fluorescence at low intensity; upon release into buffer, ANTS gives 
off a strong fluorescent signal due to diffusion away from the DPX quencher (Figure 
33A). Over a period of 16 hours, no difference in signals between liposomes containing 
the WT or ∆CR forms of PrP were observed (Figure 33B). To assess the passage of 
small ions through the membrane, we used another typical ion channel assay; in this 
technique, influx of thallium was used to measure ion passage through a membrane. 
ANTS inside the liposomes was quenched by fast entrance of thallium through 
valinomycin pores (Figure 34A); however, no quenching was observed with PrP ∆CR on 
the membrane, even over a 16 hour period (Figure 34B), indicating that thallium was not 
traveling across the membrane through open pores formed by the protein. 
 Neither of the assays we used demonstrated channel or pore formation in our 
liposome system. However, our liposome bilayers were constructed solely from neutral 
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lipids, raising the possibility that this may be an incorrect experimental model. 
Supporting this, our collaborators in the laboratory of Prof. Christian Becker (University 
of Vienna) used an anionic phospholipid (POPG) to produce liposomes that responded to 
GPI-anchored surface PrP ∆CR with calcein release (210). 
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Figure 29. Proposed toxic mechanism of a central region deletion mutant of PrP. 
Model of action for the production of spontaneous currents by the central region deletion 
mutant PrP ∆CR. (a) PrP WT, full length prion protein (23-230), is shown with the 
flexible N-terminal region sitting on the membrane surface. (b) PrP ∆CR, deletion mutant 
missing residues 105-125, is a shorter construct that allows the N-terminal residues of the 
protein to penetrate the membrane, forming a pore through which ions travel. (c) Co-
expression of WT and ∆CR forms of PrP reduces spontaneous currents. (d) PrP ∆CR∆23-
31 is missing the N-terminal region needed to penetrate the membrane.  Reprinted from 
Biasini, E., Turnbaugh, J. A., Unterberger, U., and Harris, D. A. (2012) Prion protein at 
the crossroads of physiology and disease. Trends in Neurosciences 35, 92-103 with 
permission from Elsevier. 
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Figure 30. Liposome characterization. 
Liposomes prepared by forced extrusion were analyzed using negative stain electron 
microscopy and dynamic light scattering: Liposomes were roughly uniform in size; mean 
diameter was 119 nm with polydispersity (0.048) indicating low sample heterogeneity. 
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Figure 31. Prion protein constructs. 
(A) Coomassie stained SDS-PAGE analysis of fractions eluted from a Ni2+ immobilized 
metal ion affinity column containing ∆CR-cys or WT-cys PrP. Multiple lanes represent 
individual fractions corresponding to desalting elution peaks. (B) Far-UV circular 
dichroism of correctly folded WT-cys PrP demonstrating that the cysteine adduct did not 
disrupt the secondary structure of the protein. 
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Figure 32. Sucrose gradient separates cysteine-tagged protein on liposomes. 
Western blots were immunoprobed using anti-PrP antibody, D18, and showed that 
lipsome-bound WT-cys PrP could be separated from unbound protein on a sucrose 
gradient. Protein and liposomes were loaded into the 40% sucrose layer and liposomes 
with attached proteins migrated to the 5% sucrose layer during ultracentrifugation. 
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Figure 33. The dye-quencher pair ANTS/DPX were not released from liposomes. 
(A) Control conditions in which the lipid bilayer of the liposomes were disrupted by 
detergent resulting in an increase in fluorescent intensity when ANTS was released. (B) 
Time course for ANTS release from liposomes with WT-cys, ∆CR-cys, and WT-myc 
forms of PrP; no increase in fluorescence was observed with any of the PrP proteins. 
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Figure 34. Thallium does not quench ANTS inside PrP ∆CR-containing liposomes. 
(A) Valinomycin, a pore-forming antibacterial compound, causes thallium-based 
quenching of ANTS when added to liposomes. (B) No quenching was observed for any 
of the PrP-containing liposomes that were analyzed. In this figure, dCR indicates PrP 
∆CR and vm is valinomycin. 
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